Clinical aspects of device-detected arrhythmias by Sandgren, Emma
DEPARTMENT OF CLINICAL SCIENCES,  
DANDERYD HOSPITAL  
Division of Cardiovascular Medicine,  
Karolinska Institutet, Stockholm, Sweden 







All previously published papers were reproduced with permission from the publisher. 
Published by Karolinska Institutet. 
Printed by Universitetsservice US-AB. 
Cover by Mats Ceder, Koboltart. 
© Emma Sandgren, MMXXI 
ISBN 978-91-7831-998-5 
CLINICAL ASPECTS OF DEVICE-DETECTED 
ARRHYTHMIAS 
  




Associate Professor Johan Engdahl 
Karolinska Institutet, Stockholm 
Department of Clinical Sciences  
Danderyd Hospital (KI-DS), 
Division of Cardiovascular Medicine 
 
Co-supervisors: 
Associate Professor Nils Edvardsson 
Sahlgrenska Academy at University of 
Gothenburg, Gothenburg 
Department of Molecular and Clinical Medicine, 
Institute of Medicine 
 
Professor Mårten Rosenqvist 
Karolinska Institutet, Stockholm 
Department of Clinical Sciences 
Danderyd Hospital (KI-DS), 
Division of Cardiovascular Medicine 
Opponent: 
Associate Professor Artur Fedorowski 
Lund University, Malmö 
Department of Clinical Sciences 
Skåne University Hospital 
 
Examination Board: 
Professor Mats Jensen-Urstad 
Karolinska Institutet, Stockholm 
Department of Cardiology  
Karolinska University Hospital  
 
Associate Professor Maria Eriksson 
Karolinska Institutet, Stockholm 
Department of Molecular Medicine and Surgery 
Karolinska University Hospital 
 
Associate Professor Fredrik Holmqvist 
Lund University, Lund 
Department of Clinical Sciences 







“Η γνώση είναι η τροφή του σώματος” 
 
Knowledge is the food of the soul 
Kunskap är näring för själen 
Plato, Greek philosopher, 427–347 f.Kr. 
 
In honour of my parents, Eva Nilsson and Roger Sandgren, for teaching me what is right and 







Cardiac implantable electronic devices (CIEDs) enable continuous monitoring of the heart 
rhythm. CIEDs constitute a unique opportunity for detecting arrhythmias, as the duration of 
cardiac monitoring is of the utmost importance for the detection rate. 
The CIED population consists mostly of patients from older age categories where risk factors 
for atrial fibrillation (AF) are common. A dual-chamber device can detect and store episodes 
with a high atrial rate, i.e. atrial high-rate episodes (AHREs). AHREs confirmed to be AF, 
atrial flutter or focal atrial tachycardia are termed subclinical AF. Both terms refer to patients 
with no symptoms attributed to AF, with no previous diagnosis of clinical AF. These 
episodes of device-detected AF are associated with increased risk of ischaemic stroke, 
although the risk seems to be lower than in patients with documented clinical AF, and the 
benefit of oral anticoagulation (OAC) treatment in this population has not been established. 
Patients presenting with syncope represent a diagnostic challenge. Initial evaluation can 
provide the underlying mechanism in up to half of the patients. However, the mechanism 
remains unexplained in many patients, and long-term electrocardiogram (ECG) monitoring 
with an implantable loop recorder (ILR) enables ECG recording at the time of syncope 
recurrence, which can reveal the underlying mechanism.  
The aim of this thesis is to highlight different aspects of arrhythmias diagnosed with CIEDs, 
both from a diagnostic and a therapeutic point of view. More specifically, it aims to describe 
the incidence of subclinical AF/AHREs in a pacemaker population, along with its OAC 
treatment, and the incidence of ischaemic stroke and vascular dementia. In addition, it will 
explore the role of the baseline 12-lead ECG in predicting the syncope mechanism during 
ILR monitoring, and whether age and gender impact the evaluation before the implantation 
and subsequent diagnostic yield of the ILR. Finally, the thesis will test the hypothesis that 
patients with incident AF during inpatient care after coronary artery bypass graft (CABG) 
surgery often experience a relapse of AF within a year, with little chance of detection.  
METHODS AND RESULTS 
In study I, consecutive patients were enrolled who had been implanted with a dual-chamber 
device for the indication of sinus node disease or atrioventricular block/ bundle branch block 
between 2010 and 2014 in Halland County in Sweden. The incidence of subclinical 
AF/AHREs, ischaemic stroke, or vascular dementia, and the initiation of and/or any change 
of OAC treatment were recorded during follow-up. At inclusion, 271 patients had 
clinical/known AF, of which 80% (216/271) were on OAC treatment. Four hundred eleven 
patients had no history of AF, and of these 30% (125/411) were diagnosed with subclinical 
AF/AHREs during a mean follow-up of 38 months. 62% of these were prescribed OAC 
treatment. Patients with congestive heart failure (p= .03) and age >75 years (p= .0002) were 
more often diagnosed with subclinical AF/AHREs. The annual stroke incidence was 2.1% in 
patients with clinical/known AF, 1.9% in patients with subclinical AF/AHREs, and 1.4% in 
patients with no AF. Corresponding values for a diagnosis of vascular dementia was 11.2%, 
5.6% (p= .09), and 6.2% (p= .048). 
The study population in studies II and III consisted of consecutive patients with unexplained 
syncope in Halland County in Sweden, who had been selected to be implanted with an ILR 
after an initial non-diagnostic evaluation between 2007 and 2016. In study II, baseline 12-
lead ECG was compared with clinically adjudicated cause of syncope. In study III the role of 
age and gender in the evaluation before implantation, and in the diagnostic yield of the ILR, 
was reported. There is a notable difference between the two terms ILR-guided diagnosis 
(study II) and ECG-based diagnosis (study III). ILR-guided diagnosis refers to all patients 
where the ILR has informed the clinical diagnosis, i.e. where captured ECG recordings both 
during syncope recurrence or other times have enabled a clinical diagnosis to be made, while 
ECG-based diagnosis only includes patients with syncope recurrence. In total, 300 (147 
women) patients were included. The mean age was 66±16 years. In study II, 49% (146/300) 
received an ILR-guided diagnosis. Bifascicular block was the second most common 
pathological baseline 12-lead ECG finding (n=33). It was most common in patients ≥60 years 
of age (31/33), and more common in patients who received an ILR-guided diagnosis 
(bifascicular block: 25/33, 76%; normal baseline 12-lead ECG: 90/205, 44%, p< .001). 
Among patients with bifascicular block, 96% (24/25) were clinically adjudicated to have an 
arrhythmia-caused syncope, and of these, 23 had ECG recordings of a bradyarrhythmia. 
Bifascicular block was a strong predictor of a clinically adjudicated arrhythmia-caused 
syncope, with an adjusted odds ratio of 5.5 (95%CI (confidence interval) 2.3-13.2), p< .001, 
and a positive predictive value of 73%. In the total population, bifascicular block predicted a 
clinically adjudicated arrhythmia-caused syncope due to bradyarrhythmia, with an adjusted 
odds ratio of 11.4 (95%CI 5.0-26.2), p< .001. In study III, women experienced syncope 
recurrence and received an ECG-based diagnosis more often than men (women: 56/147, 
38%; men: 33/153, 22%; p= .001), mainly because of a higher incidence of non-arrhythmic 
syncope recurrence, i.e. syncope with a normal ECG recording (women: 27/147, 18%; men: 
15/153, 10%; p= .045). Patients ≥60 years of age had the lowest rate of pre-implant tests (<40 
years: 6.5±1.2; 40-59 years: 5.75±1.0; and ≥60 years: 5.1±1.9; p= .002) but the highest rate of 
arrhythmic syncope (<40 years: 3/11, 27%; 41-59 years: 7/18, 39%; and ≥60 years: 37/60, 
62%; p= .045). Fifty patients with no recurrent syncope had ECG findings potentially 
indicative of recurrent syncope.  
Study IV was a sub-study of the prospective AFAF study (Atrial Fibrillation AFter CABG 
and percutaneous coronary intervention). In short, the AFAF study investigates the incidence 
of AF after percutaneous coronary intervention or CABG surgery by non-invasive handheld 
ECG recordings. It is investigated three times daily during the first postoperative month, and 
thereafter for two weeks at three, 12 and 24 months in addition to routine care. This sub-study 
added continuous ECG monitoring with an ILR. The primary endpoint was the proportion of 
patients with incident or recurrent AF during the 12-month monitoring period. The secondary 
endpoints were the proportion of patients who developed persistent AF and calculated AF 
 
 
burden. In total, 27/40 (68%) patients were diagnosed with incident AF, 21 in hospital and six 
later. Eighteen of these 27 (67%) also experienced AF recurrence, and three patients 
progressed into persistent AF. The incidence of AF episodes was highest during the first 30 
postoperative days, as 17/40 patients had episodes of AF after discharge within this period. 
The rate of incident and recurrent AF after the first 30 days was low: three patients had 
incident AF and 10 patients recurrent AF. The CHA2DS2-VASc (Congestive heart failure, 
Hypertension, Age >75 years (2 points), Diabetes, Stroke (2 points), Vascular disease, Age 
65-74 and Sex (female)) score was higher in patients with AF than in patients who remained 
in sinus rhythm: median 4 (IQR (interquartile range) 1) and median 3 (IQR 2) respectively, 
p= .006. In patients with paroxysmal AF, the AF burden was low: 0.1% (IQR 0.28). 
Handheld ECG identified fewer patients with AF after discharge than the ILR (handheld 
ECG: 9/20, 45%; ILR: 20/20, 100%; p= .001).  
CONCLUSIONS 
CIEDs are a valuable asset in arrhythmia diagnostics, and can inform clinical decisions. 
Subclinical AF/AHREs were common, and were associated with older age and congestive 
heart failure. The stroke incidence was low, but clinical/known AF was associated with an 
increased risk of vascular dementia. 
In syncope patients bifascicular block at baseline 12-lead ECG predicted a clinically 
adjudicated arrhythmia-caused syncope, commonly due to intermittent complete heart block.  
Women experienced syncope recurrence more often than men, especially for non-arrhythmic 
reasons. The highest rate of arrhythmic syncope and the lowest rate of pre-implant tests were 
found in patients ≥60 years of age. 
In patients treated with CABG surgery, the recurrence rate of AF was high in patients with 
incident AF during hospitalisation, especially during the first postoperative month. After the 
first month, the rate of incident and recurrent AF was low. The ILR was more effective in 
detecting patients with AF than handheld ECG. 
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opportunity to spend every day with arrhythmias and devices is a dream for someone who 
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interest in undertaking research, and when he gave me the chance to be one of his Ph.D. 
students, I took the opportunity. It was also Johan who introduced me to Nils and Mårten, and 
when Nils called some months later and asked whether I was interested in conducting a study, 
my supervisors were appointed. Since then, I have spent even more time trying to grasp, treat 
and understand the nature and meaning of device-detected arrhythmias. Along the way I have 





















2 GENERAL INFORMATION ON THE THESIS 
2.1 FLOWCHART  
This thesis consists of four studies. Two of them (studies II and III) involve the same study 
population as delineated in Figure 1, and described in more detail in the Patients and Methods 
section. 
 
Figure 1. Flowchart of the thesis. AFAF, Atrial Fibrillation AFter CABG and percutaneous 








3  INTRODUCTION 
3.1 THE PACEMAKER 
3.1.1 History and development of modern pacing 
Modern cardiac electrophysiology is based on two important discoveries involving organic 
tissue. First, the fact that electricity is an inherent part of organic tissue was described by 
Luigi Galvani in 1791 (Figure 2) (1). Second, the fact that the success of electrical stimuli to 
the heart depends on applying pulsed stimuli established at the end of the nineteenth century 
by J A McWilliam. The latter also forms the basic concept of modern pacing (2).  
These two important discoveries paved the way for the development of the first pacemaker. 
In 1928, the Australian anaesthesiologist Mark C Lidwell developed the first pacemaker (1), 
followed closely by the construction of an electro-mechanical device in 1932 by the 
American cardiologist Albert S Hyman, who was the first to use and popularise the term 
“artificial pacemaker” (3). The next advancement came in 1952, when Doctor Wilfred 
Bigelow, Doctor Johan Callaghan and engineer Jack Hopps succeeded in stimulating 
endocardial tissue using a bipolar electrode on the distal tip of a small catheter. They were 
credited with the first endocardial electrode placement, as well as the first pacemaker circuit 
(4, 5). Another pioneer in the evolution of artificial pacemakers was cardiologist Paul Zoll. At 
the beginning of the 1950s, he reported the successful use of a complete external artificial 
pacemaker system with skin electrodes, to treat cardiac standstill (6). Zoll was also one of the 
first to use rechargeable batteries as a power source (5).  
The widespread use of pacemakers was limited by the large, bulky external energy sources 
required, but the advent of the transistor in 1948 enabled the development of smaller 
implantable sources of energy (1). First came a wearable, external, battery-operated, 
transistorised artificial pacemaker constructed by the American engineer Earl Bakken 
(founder of Medtronic) at the beginning of 1958 (7). In the autumn of the same year, the 
Swedish cardiac surgeon Åke Senning and the Swedish physician and inventor Rune 
Elmqvist succeeded in incorporating these new transistors into a pulse generator small 
enough to implant under the skin in the epigastrium. In October 1958, this made the first 
implantation of a fully implantable system possible at Karolinska Hospital in Solna (Figure 
3). The electrodes were attached to the myocardium of the heart by thoracotomy. In the 
1960s, transvenous leads replaced epicardial leads (1), and the pulse generators were placed 








Figure 2. A drawing from Luigi Galvani’s De Viribus Electricitatis in Motu Musculari 
Commentarius, showing his experiments in electrophysiology. The Wellcome Collection 
(https://wellcomecollection.org). Licensed under CC BY 4.0 
(https://creativecommons.org/licenses/by/4.0/). 
In the following decades new features were developed, improving the technical performance 
of pacemakers. In the 1960s, “demand” pacemakers were introduced to sense underlying 
cardiac activity, which ensured the pacemaker only provided pacing when needed. In the 
mid-1970s pacemakers were made programmable in a non-invasive way, through radio-
frequency telemetry links. In 1978, the dual-chamber pacemaker was developed to pace and 
sense in both atria and ventricles. Late in the 1980s, rate-responsive pacemakers were 
introduced so that the pacing rate could change according to the patient’s activity level. In the 
1990s, microprocessors were incorporated into pacemakers, enabling features which allowed 
events to be detected and stored, and pacing functions to be changed automatically (5).  
Parallel to this technological development, knowledge of the hemodynamic effects of pacing 
improved, as did awareness of the risk of infection associated with implantable leads and 
generators. This resulted in the development of alternative pacing strategies. In the 1990s, 







evolving, as was the technology associated with it. This made widespread introduction of 
cardiac resynchronisation therapy possible in the beginning of the 21st century (9). In the mid-
2010s, the concept of leadless pacing was introduced (10, 11). At the same time, conduction 
system pacing emerged as an alternative to right-ventricular and bi-ventricular pacing. 
Conduction system pacing maintains a physiological pattern of ventricular electrical 
activation via the native His-Purkinje system (12-15).  
 
Figure 3. First implanted pacemaker, constructed by Rune Elmqvist and implanted at 
Karolinska Hospital in 1958 by the surgeon Åke Senning. Dimensions of the pacemaker: 
diameter: 55 millimetres, and thickness: 16 millimetres. Picture from “A brief history of 
cardiac pacing” by O Aquilina, 2006. Images in Paediatric Cardiology, 8, 17-81 
(https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3232561/). Copyright © 2006 Images in 








3.2 ATRIAL FIBRILLATION 
3.2.1 Prevalence of atrial fibrillation 
Atrial fibrillation (AF) is the most common clinically significant cardiac arrhythmia, and 
prevalence increases with advancing age. Prevalence is reported to be approximately 3% in 
the adult population (16), and reaches 8-10% at the age of 80 years (17). As AF is often 
asymptomatic, there are large numbers of undetected cases (18). Moreover, with stable 
prevalence, a large increase in the number of adults with AF is predicted in the coming 
decades, due to an ageing population (19).  
AF is associated with increased morbidity and mortality. For instance, AF predisposes for 
congestive heart failure (20). It is associated with a twofold increased risk of all-cause 
mortality (21) and a fivefold increased risk of ischaemic stroke (22). Furthermore, AF is 
associated with increased risk of developing dementia (23, 24). 
3.2.2 Diagnosis and classification of atrial fibrillation 
An electrocardiogram (ECG) recording showing irregularly irregular RR intervals and no 
discernible, distinct P-waves is required to diagnose AF. By convention, a single-lead ECG 
recording lasting at least 30 seconds or an entire 12-lead ECG is diagnostic of clinical AF 
(20). The atrial cycle length is usually less than 200 milliseconds, i.e. an atrial rate greater 
than 300 beats per minute (bpm) (25). 
AF is by convention classified into five different types based on the presentation, the duration 
and whether the episodes with AF terminate spontaneously (20). 
§ First diagnosed AF – first AF episode in a patient without prior history of AF. 
§ Paroxysmal AF – AF terminates within seven days (spontaneously or with 
intervention). 
§ Persistent AF – an AF episode lasting for more than seven days, or where 
cardioversion is needed to restore sinus rhythm after seven or more days. 
§ Long-standing persistent AF – an AF episode lasting for more than one year, where 
the aim is to restore sinus rhythm. 
§ Permanent AF – continuous AF, where the arrhythmia is accepted by the physician 
and patient, and no rhythm control interventions are applicable.  
3.2.3 Pathophysiology and risk factors for atrial fibrillation 
AF is defined as a supraventricular arrhythmia which is characterised by chaotic and irregular 







trigger, and it is maintained through an appropriate anatomic substrate (26). In 1998, 
Haissaguerre et al. showed that the pulmonary veins were an important source of ectopic 
beats, and that this was where 94% of all focal triggers responsible for initiating AF were 
situated (Figure 4) (27). Advancing age and underlying heart disease, such as coronary artery 
disease, valvar heart disease, cardiomyopathies, heart failure and AF itself, induce a slow but 
progressive process of structural remodeling of the atrial architecture. This remodeling is 
enhanced by external stressors such as hypertension, obesity, diabetes, sleep apnoea and 
alcohol or drugs. The structural remodeling with areas of fibrosis results in electrical 
dissociation between muscle bundles and local conduction heterogeneities, favouring re-entry 
and maintaining of AF (26).  
 
Figure 4. Diagram of the distribution of 69 foci triggering AF in 45 patients. AF, atrial 
fibrillation. Reprinted with permission from “Spontaneous initiation of atrial fibrillation by 
ectopic beats originating in the pulmonary veins” by Haïssaguerre M, Jaïs P, Shah DC, et 
al., 1998. New England Journal of Medicine, 339, 659-666. Copyright © 1998 Massachusetts 
Medical Society. 
These above-mentioned structural changes and electrophysiological disturbances in the atrial 
myocardium are different manifestations of atrial cardiomyopathy, which is defined as any 
complex of structural, architectural, contractile or electrophysiological changes affecting the 
atria, with the potential to produce clinically relevant manifestations (28). The atrial myocardial 







on the endothelia surface, and activation of platelets and inflammatory cells which, in 
combination with stasis of blood, generate a prothrombotic milieu (Figure 5) (29-31). This 
activation of the coagulation system partially explains why short episodes of AF imply a long-
term risk of stroke. It should also be emphasised that atrial cardiomyopathy has a strong impact 
on atrial arrhythmogenesis, e.g. the occurrence of AF.  
In addition to the contribution from atrial cardiomyopathy, AF itself gives rise to structural 
changes which favour its own maintenance (32). AF, with its high-frequency atrial 
excitations, leads to ion-channel remodeling, abbreviating the duration and refractory period 
of the action potential which enhance its stabilisation. In the short term (minutes, hours, 
days), AF-induced electrical remodeling is reversible, but becomes less so with longer 
duration (months, years) (28). 
3.2.4 Risk of stroke, and anticoagulation treatment in atrial fibrillation 
The structural changes in the atrial myocardium, in combination with the stasis in blood flow 
due to loss of atrial contraction, generate a prothrombotic milieu, especially in the left atrial 
appendage. Consequently, there is a manifold increased risk of ischaemic stroke in patients 
with AF. This increased risk is independent of AF symptoms (33). Therefore, all patients 
with AF, with or without symptoms, should be evaluated in terms of thromboembolic risk. 
The European Society of Cardiology (ESC) and the Swedish healthcare authorities 
recommend using the CHA2DS2-VASc (Congestive heart failure, Hypertension, Age >75 
years (2 points), Diabetes, Stroke (2 points), Vascular disease, Age 65-74 and Sex (female)) 
score. Oral anticoagulation (OAC) treatment should be considered for men and women with a 
CHA2DS2-VASc score of one and two points respectively. For men with CHA2DS2-VASc 
scores of two or more, and for women with three or more, OAC treatment is recommended to 
prevent thromboembolism (20, 34). In individuals with increased risk of embolic stroke, 
OAC treatment reduces the ischaemic stroke risk by 60-70% (35). The advances in stroke 
prevention and potential areas for further improvements were recently highlighted in a 
systematic review (36).   
Alternative systems for risk prediction are currently being evaluated, such as the ABC AF 
study (ABC-Scores for Reduction of Stroke and Mortality in Atrial Fibrillation, 
NCT03753490), which randomise patients to specific OAC treatment based on ABC (age, 
biomarkers, clinical history) stroke and bleeding risk scores, or standard treatment. In 
addition to clinical characteristics, the ABC risk score is based on biomarkers, to improve the 
prognostication of stroke and bleeding in patients with AF (37). The biomarker-based risk 








Figure 5. The relationship between atrial myopathy, AF and ischaemic stroke. Atrial 
myopathy is induced by ageing, inflammation, oxidative stress and stretching of the atria. 
Atrial myopathy leads to electrophysiological and architectural changes in the atrial 
myocardium, alters the properties of the cardiac autonomic nervous system and results in 
endothelial dysfunction and stasis, thereby contributing to a prothrombotic state. The 
electrophysiological and architectural changes facilitate the development of AF, which in 
turn causes more inflammation, fibrosis and autonomic remodeling. All these changes lead to 
a prothrombotic milieu mediated by circulating inflammatory molecules. CRP, C-reactive 
protein; TNF, tumour necrosis factor; vWF, von Willebrand factor. Reprinted with 
permission from “Atrial Myopathy” by Shen MJ, Arora R, Jalife J, 2019. Journal of the 
American College of Cardiology: Basic to Translational Science, 4, 640-654 
(https://www.jacc.org/doi/full/10.1016/j.jacbts.2019.05.005). Copyright © 2019 The Authors. 







3.3 DEVICE-DETECTED ATRIAL FIBRILLATION 
3.3.1 Definition of an atrial high-rate episode and subclinical atrial fibrillation 
Implantable devices with an atrial lead can detect and store episodes with a high atrial rate, 
i.e. atrial high-rate episodes (AHREs). Most modern dual-chamber pacemakers have specific 
AF-detection algorithms, while others have “atrial high-rate episode” detection algorithms 
which provide an opportunity to collect information about the number of episodes, the date 
and time of the onset of episodes, the duration of episodes and AF burden over time. Most 
devices can store intra-atrial electrograms (EGMs) for detected episodes, to allow the 
captured arrhythmia to be visually adjudicated (Figure 6). The definition of an atrial high-rate 
episode is an atrial tachyarrhythmia episode with a rate >175-190 bpm, lasting at least five 
minutes and detected by implantable cardiac devices (20, 41). Accordingly, atrial 
tachyarrhythmias other than AF, such as atrial flutter and focal atrial tachycardia might be 
detected as AHREs. However, only a minority of AHREs are not AF or atrial flutter (42, 43). 
Importantly, EGMs must be visually inspected to identify false positives due to electrical 
artefacts or oversensing. The term subclinical AF includes AHREs confirmed to be AF, atrial 
flutter or focal atrial tachycardia, as well as AF episodes detected by an implantable loop 
recorder (ILR) or a wearable monitor and confirmed by visual inspection of EGMs or ECG 
recordings. There is no specific rate limit for subclinical AF. Note in particular that these two 
terms refer to patients with no symptoms attributed to AF, with no previous diagnosis of 
clinical AF, i.e. no 12-lead ECG or rhythm strip documenting AF. Asymptomatic AF in 
patients with AF verified by a 12-lead ECG or a rhythm strip is called silent AF (20, 41).  
 
Figure 6. Episode stored as an atrial high-rate episode in a dual-chamber pacemaker. EGM 
1 – atrial EGM. EGM 2 – ventricular EGM and marker channel. EGM 3 – far-field EGM. 







3.3.2 Atrial high-rate episodes as a proxy for atrial fibrillation 
AF-detection algorithms nevertheless have their limitations, and all cardiac rhythm 
recordings obtained from implantable devices require adjudication or review to verify 
diagnostic accuracy. For reliable AF detection by devices, a bipolar atrial lead is required to 
minimise the risk of inappropriate detection, as unipolar leads are more prone to oversensing 
issues due to their longer inter-electrode distance (tip to can for unipolar versus tip to ring for 
bipolar leads). Preferably, high atrial sensitivity is programmed to avoid intermittent atrial 
undersensing of AF, which can result in inappropriate detection of persistent AF as multiple 
short episodes. High atrial sensitivity may increase the risk of far-field R-wave oversensing, 
and this can be avoided by adjusting the post-ventricular atrial blanking interval (44, 45).  
The programmed cut-off values for AHRE detection rate and duration are also important, as 
these influence the number of automatic mode switch episodes. A higher detection rate and 
duration reduce the risk of false positive recordings. In terms of cut-off values, Pollak et al. 
reported that only 18% of AHREs with a rate of <250 bpm were true atrial arrhythmias 
(confirmed by atrial EGMs), compared to 57% of episodes with a rate of >250 bpm (p< 
.001). In the same study, 91% of all EGMs verified as AF episodes had an atrial rate of >250 
bpm (46). In term of duration, a good correlation has been reported between AHREs and 
ECG-documented AF, particularly when the episode lasts over five minutes (46-48). Shorter 
episodes often represent oversensing due to e.g. far-field R- or T-wave oversensing, or non-
sustained atrial premature contractions (48, 49). For example, Pollak et al. reported that 18% 
of all AHREs shorter than 10 seconds represented true atrial arrhythmias (verified by atrial 
EGMs), compared to 89% of all episodes with a duration of five minutes or more (p< .001) 
(46). On the other hand, Kaufman et al. showed that the rate of false positive AHRE 
recordings was 17.3% with a cut-off of six minutes and >190 bpm, while the percentage 
decreased to 3.3% when the AHRE duration was extended to at least six hours (50). Both 
studies illustrate the importance of reviewing stored recordings, especially those with a short 
duration.  
A majority of all subclinical AF/AHREs are asymptomatic. A-HIRATE (The Atrial High 
Rate Episodes) investigators have reported first that, out of all the days where a patient 
reported symptoms, no subclinical AF/AHRE was recorded on 92.4% of the days. Second, 
they reported that just one percentage of subclinical AF/AHREs in patients with newly 








3.3.3 Incidence of device-detected atrial fibrillation  
Episodes of device-detected AF are common, and are associated with increased morbidity 
and mortality in patients with implantable devices. A review by Nielsen et al. reported an 
annual incidence of 5% after pacemaker implantation, with a mean lifetime cumulative 
incidence of 30-40%. Important predictors of device-detected AF were tachycardia-
bradycardia syndrome, sick sinus syndrome and VVI pacing (52). In two studies, one 
including patients implanted with a pacemaker due to sick sinus syndrome and one including 
all patients with pacemakers capable of detecting AF, the incidence of device-detected AF 
was reported to be 51.3% for 27 months and 55.3% for six months of follow-up respectively 
(53, 54). Predictors of device-detected AF were older age group, history of clinical AF and 
larger left atrial volume (54). In turn, the presence of device-detected AF was an independent 
predictor of total mortality, death or non-fatal stroke and development of clinical AF (53). 
When patients with a history of clinical AF are excluded, the incidence is reported to be 30-
34.7% during 1-2.5 years of follow-up (55-57). The occurrence of device-detected AF was 
associated with increased risk of ischaemic stroke and systemic embolism (56), and even if 
the incidence of device-detected AF was independent of the CHADS2 (Congestive heart 
failure, Hypertension, Age >75 years, Diabetes, Stroke (2 points)) score, a higher CHADS2 
score was associated with increased risk of device-detected AF with a duration of more than 
six hours (55). A summary of the major studies in the field of AHRE incidence are seen in 
Figure 7 (58). 
3.3.4 Device-detected atrial fibrillation and the risk of ischaemic stroke  
Several observational and randomised studies have documented that subclinical AF/AHREs 
detected by implantable devices are associated with increased risk of subsequent ischaemic 
stroke and systemic embolism. In the MOST (The Mode Selection Trial) trial in 2003, 
subclinical AF/AHREs with a duration of at least five minutes were associated with a 2.79-
fold (95%CI (confidence interval) 1.51-5.15) increased risk of thromboembolic events (53), 
while the TRENDS (A Prospective Study of the Clinical Significance of Atrial Arrhythmias 
Detected by Implanted Device Diagnostics) study in 2009 showed a doubled risk of 
thromboembolic events for an AF burden of more than 5.5 hours on any single day during a 
30-day period (59). The ASSERT (Asymptomatic Atrial Fibrillation and Stroke Evaluation in 
Pacemaker Patients and the Atrial Fibrillation Reduction Atrial Pacing Trial) trial in 2012 
reported that subclinical AF/AHREs of at least six minutes’ duration were associated with a 








Figure 7. Incidence of device-detected AF, i.e. subclinical AF/AHREs on the basis of data 
from literature (53, 56, 57, 59-66). AF, atrial fibrillation; AHRE, atrial high-rate episode; 
CIED, cardiac implantable electronic device; SVT, supraventricular tachycardia. Reprinted 
with permission from “What do we do about atrial high-rate episodes?” by Boriani G, Vitolo 
M, Imberti JF, et al., 2020. European Heart Journal Supplements, 22, O42-O52 
(https://academic.oup.com/eurheartjsupp/article/22/Supplement_O/O42/6043870). Copyright 
© 2020 The Authors. Licensed under CC BY-NC-ND 4.0 
(https://creativecommons.org/licenses/by-nc-nd/4.0/).   
during 2.5 years of follow-up in patients with an age of 65 years or more, in combination with 
hypertension, but with no history of clinical AF (56). In this vein, the SOS AF (Stroke 
PreventiOn Strategies based on Atrial Fibrillation information from implanted devices) study 
in 2014 continued to demonstrate increased risk of ischaemic stroke or transient ischaemic 
attack with AF burden of at least five minutes respective one hour per day, with hazard ratios 
of 1.76 and 2.11 respectively (63). Although these studies have different thresholds for 
subclinical AF/AHRE duration, often arbitrarily chosen, they all have in common that they 
indicate an increased risk of thromboembolic events for subclinical AF/AHREs, even if the 
risk seems to be lower than for clinical documented AF (20, 43). Two systematic reviews 
have been published on this topic, both including some of the above-mentioned studies. The 
first focused on the importance of subclinical AF/AHRE duration for stroke risk, and two 
meta-analyses were conducted, the first indicating increased risk of thromboembolic events in 
patients with a subclinical AF/AHRE burden of over six minutes, compared to those with no 
subclinical AF/AHREs. The second showed an increased risk of stroke only for those with a 







determine the stroke risk for patients with subclinical AF/AHREs. It showed that subclinical 
AF/AHREs strongly predict clinical AF with an odds ratio of 5.7, and are associated with a 
2.4-fold increased risk of stroke (Figure 8) (68). A recent article summarises the evidence in 
terms of subclinical AF/AHREs and their impact on the risk of stroke. The article concludes 
that the presence of subclinical AF/AHREs increases the risk of stroke by 0.8-1.0% per year, 
and that subclinical AF/AHREs of longer duration (>24 hours) may be associated with higher 
risk of stroke (69). 
 
Figure 8. Forest plots demonstrating: A: Association between subclinical AF/AHREs and 
clinical AF. B: Association between subclinical AF/AHREs and stroke risk. AF, atrial 
fibrillation; AHRE, atrial high-rate episode; CI, confidence interval; SE, standard error. 
Reprinted with permission from “Subclinical device-detected atrial fibrillation and stroke 
risk: a systematic review and meta-analysis” by Mahajan R, Perera T, Elliott AD, et al., 
2018. European Heart Journal, 39, 1407-1415. Copyright © 2018 Oxford University Press.  
Despite the fact that the occurrence of device-detected AF is associated with increased risk of 
thromboembolic events, no temporal relationship has been shown between subclinical 
AF/AHREs and ischaemic stroke. Analyses from the TRENDS trial and ASSERT trial report 
that 73% and 92% of patients had no AF burden within 30 days prior to an ischaemic stroke 
or systemic embolism (70, 71). Most likely, the stroke risk depends on an interplay between 
traditional stroke risk factors and AF burden, and the above-mentioned observation about no 
temporal relationship, has led to the argument that AF should be seen as a risk marker rather 








Figure 9. The association between AF and ischaemic stroke conceptualised in two models: 
AF as a risk marker and AF as the direct cause. AF, atrial fibrillation; LAA, left atrial 
appendage; PAF, paroxysmal AF. Reprinted with permission from “AHA Scientific 
Statement: Subclinical and Device-Detected Atrial Fibrillation: Pondering the Knowledge 
Gap” by Noseworthy PA, Kaufman ES, Chen LY, et al., 2019. Circulation, 140, e944-e963. 
Copyright © 2019 American Heart Association, Inc.  
3.3.5 Device-detected atrial fibrillation and anticoagulation treatment 
There is convincing evidence that device-detected AF is associated with increased risk of 
thromboembolic events, but there is a lack of evidence whether these patients require the 
same therapeutic action as patients with clinical documented AF (73). As mentioned above, 
the stroke risk seems to be lower than for clinical AF. 
Another knowledge gap involves whether there is a cut-off value for the subclinical 
AF/AHRE burden (proportion of time spent in subclinical AF/AHREs divided by the total 
amount of time the patient is monitored (74)) when OAC treatment will give a net benefit, or 
if there is a continuous increase in thromboembolic risk following increased duration of AF. 
In a recent analysis from the ASSERT trial, Van Gelder et al. reported that only episodes 
longer than 24 hours were associated with a threefold increased risk of thromboembolic 







between short episodes of subclinical AF/AHRE and the risk of ischaemic stroke (43, 76). 
This could justify OAC for all patients with subclinical AF /AHREs at risk of stroke, with the 
reservation that no results from randomised clinical trials have yet been published (36).  
In the absence of solid evidence from randomised trials, there are rather divergent 
recommendations from the ESC, the European Heart Rhythm Association (EHRA) and the 
American College of Cardiology/American Heart Association/Heart Rhythm Society 
(ACC/AHA/HRS) regarding OAC treatment for subclinical AF/AHREs (Figure 10 and Table 
1) (20, 41, 77).  
 
Figure 10. Proposed management of subclinical AF/AHREs. AF, atrial fibrillation; AHRE, 
atrial high-rate episode; CHA2DS2-VASc, (Congestive heart failure, Hypertension, Age >75 
years (2 points), Diabetes, Stroke (2 points), Vascular disease, Age 65-74 and Sex (female)); 
f, female; h, hour; m, male; OAC, oral anticoagulation; SCAF, subclinical AF. Reprinted 
with permission from “2020 ESC guidelines for the diagnosis and management of atrial 
fibrillation” developed in collaboration with the European Association of Cardio-Thoracic 
Surgery” by Hindricks G, Potpara T, Dagres N, et al., 2020. European Heart Journal, 00, 1-









Table 1. Recommendations regarding OAC treatment in patients with subclinical AF/AHREs. 
ESC (20) Implantable devices should be interrogated on a regular basis for 
AHREs (class I). 
Patients with subclinical AF/AHREs should undergo: 
• Complete cardiovascular evaluation with ECG recording, and 
thromboembolic risk assessment using the CHA2DS2-VASc 
score (class I). 
• Intense follow-up to detect clinical AF and to reassess 
subclinical AF/AHRE burden (class I). 
Considered OAC treatment in patients with long episodes of 
subclinical AF/AHRE (i.e. ≥24 hours) at high risk of stroke 
(CHA2DS2-VASc ≥2 in men and ≥3 in women), provided that AF is 
verified by a simultaneous EGM recording. 
EHRA (41) EGMs should be reviewed when available.  
Subclinical AF/AHRE duration over 5.5 hours can justify OAC 
treatment when CHA2DS2-VASc criteria are fulfilled.  
A shorter subclinical AF/AHRE duration can merit OAC when 
multiple risk factors are present. 
In patients with only a five-minute episode of subclinical AF/AHRE, 
observation of the subclinical AF/AHRE burden is recommended 
before OAC is started. 
AHA/ACC/HRS 
(77) 
The presence of subclinical AF/AHREs prompts further evaluation for 
clinically relevant AF (class I). 
ACC, American College of Cardiology; AF, atrial fibrillation; AHA, American Heart 
Association; AHRE, atrial high-rate episode; CHA2DS2-VASc, (Congestive heart failure, 
Hypertension, Age >75 years (2 points), Diabetes, Stroke (2 points), Vascular disease, Age 
65-74 and Sex (female)); ECG, electrocardiogram; EGM, electrogram; EHRA, European 
Heart Rhythm Association; ESC, European Society of Cardiology; HRS, Heart Rhythm 







Three ongoing randomised trials ARTESiA (Apixaban for the Reduction of Thrombo-
Embolism in Patients With Device-Detected Sub-Clinical Atrial Fibrillation, NCT01938248), 
NOAH-AFNET 6 (Non-Vitamin K Antagonist Oral Anticoagulants in Patients With Atrial 
High Rate Episodes, NCT02618577) and SILENT (Subclinical Atrial Fibrillation and Stroke 
Prevention Trial, NCT02004509) will improve knowledge on how to manage OAC in 







Table 2. Ongoing trials evaluating OAC treatment in patients with subclinical AF/AHREs. 
 Inclusion criteria Treatment arms Primary outcome Compl. 
ARTESiA 
(78) 
Patients ≥55 years with AHREs 
(>6 minutes, but <24 hours 
duration) and additional stroke-
risk factors. 
Apixaban, 5 mg twice daily (2.5 mg twice daily when 
appropriate) or aspirin, 81 mg daily. 
Composite, consisting of 







Patients ≥65 years with AHREs 
(>6 minutes duration) detected 
at least two months after 
implantation. 
Endoxaban 60 mg once a day (30 mg once a day 
when appropriate), or 100 mg acetylsalicylic acid plus 
placebo matching endoxaban or placebo matching 
acetylsalicylic acid plus placebo matching endoxaban. 
Time to first occurrence of stroke, 
systemic embolism or 
cardiovascular death with a time 





Patients aged ≥18 years with 
CHADS2 score ≥2 and sinus 
rhythm. 
Experimental arm: collection of device data every two 
months and OAC if AHREs >5.5 hours per day. 
Active comparator arm: no device data are analysed.  
Clinical AF are treated at the physician’s discretion. 




AF, atrial fibrillation; AHRE, atrial high-rate episode; CHADS2, Congestive heart failure, Hypertension, Age >75 years, Diabetes, Stroke (2 points); 







3.3.6 Remote monitoring 
Remote monitoring of implantable devices is safe and effective for early detection of atrial 
arrhythmias, particularly AF (81-83), but it is not clear whether it improves clinical outcome. 
The IMPACT (Combined Use of BIOTRONIK Home Monitoring and Predefined 
Anticoagulation to Reduce Stroke Risk) study, designed to investigate initiation and 
termination of OAC treatment through remote monitoring of AF, failed to show a reduction 
in the primary outcomes: stroke and bleeding incidence (64). The neutral outcome may have 
been affected by the low number of newly diagnosed AF cases, which in turn may be due to 
the low mean age of the study population. Furthermore, OAC treatment was underused, and 
most importantly there were low number of endpoints due to study design. Therefore, even if 
the usefulness of remote monitoring for early detection of AF is documented, it remains to be 
demonstrated whether initiating of OAC treatment for subclinical AF/AHREs guided by 
remote monitoring improves clinical outcomes and reduces the risk of stroke and systemic 
embolism. In this context, it should also be mentioned that remote monitoring is associated 
with costs for device and sometimes with increased workload.  
3.4 THE IMPLANTABLE LOOP RECORDER 
3.4.1 History and basic concepts of the implantable loop recorder 
The ILR was developed in the early 1990s (84, 85), and is a small device, capable of 
detecting and storing episodes of arrhythmia. It is usually implanted subcutaneously in the 
left parasternal region under local anaesthetic. Initially, cutaneous mapping techniques were 
used to help position the device (86), but fairly soon anatomical approaches were developed, 
and superseded the time-consuming mapping methods (87, 88). This was followed by the 
launch of injectable devices in 2014, which further simplified the implantation procedure 
(88).  
The ILR has a pair of built-in sensing leads located on the shell of the device, to allow a 
single-lead bipolar ECG to be recorded. The device operates in “loops”, which means that it 
continuously monitors ECG signals in time windows. In older devices, the patient or 
someone else had to activate the memory or “freeze the loop”, but this shortcoming was 
resolved with automatic detection in newer models. The device stores ECG data 
automatically if predefined criteria for brady- or tachyarrhythmia are met, or in response to 
patient activation. Newer devices also include specific algorithms for atrial tachycardia and 
AF detection. Stored episodes can be downloaded via radio frequency with a special 
programmer. Battery longevity is 36-48 months, depending on the device model and the 







3.4.2 Limitations of implantable loop recorder diagnostics  
One of the drawbacks of single-lead ECG is its inability to obtain a clean and stable signal, 
due to a susceptibility to interference. Oversensing episodes due to artefacts are common, as 
well as undersensing episodes due to decreased signal amplitude or baseline drift. In turn, this 
leads to non-diagnostic interrogations, which limit the clinical value (91, 92). To minimise 
the influence of myopotentials, the electrodes should be introduced facing the skin (86). The 
signal quality can also be hampered by the subcutaneous position, risking migration of the 
device, which can cause reduced signal amplitudes over time (85). To avoid this problem, it 
is important to choose an appropriate implantation site and create a tight subcutaneous 
pocket. This is facilitated by the new injectable devices (93). 
Another possible drawback of ILR monitoring is its limited memory capacity, leading to a 
risk of memory saturation as a result of frequent arrhythmia episodes and/or episodes with 
inappropriate under- or oversensing, meaning that data are lost. This limitation can be 
resolved with regular in-office visits, or by offering the patient remote monitoring. Remote 
monitoring of ILRs has the potential to avoid loss of data, which could be overwritten, and to 
facilitate earlier diagnosis of asymptomatic events (94). It also saves time and effort for the 
patient, who does not need to visit the hospital so often. Although remote monitoring has the 
above-mentioned advantages, it risks introducing a need for data to be reviewed more often. 
3.5 SYNCOPE 
3.5.1 Definition and prevalence of syncope 
Syncope is a clinical syndrome characterised by transient and self-limited loss of 
consciousness (95) and postural tone due to cerebral hypoperfusion, with complete recovery.   
Syncope is a common reason for visits to emergency departments, and its incidence and 
prevalence are age-dependent. Current estimates show that syncope accounts for 3% of all 
visits to emergency departments, and 6% of all hospitalisations (96-98). The prevalence is 
high, with a lifetime experience of 42% in a general population. It increases with age, 









3.5.2 Pathophysiology and classification of syncope 
The pathophysiological basis for classifying syncope centres on a fall in systemic blood 
pressure with a decrease in global cerebral blood flow, and 6-8 seconds of cessation of 
cerebral blood flow are sufficient to cause syncope. Systemic blood flow is the product of 
total peripheral resistance and cardiac output, and a fall in either can cause syncope. Usually 
both mechanisms act together to a varying degree to cause syncope.  
Syncope can be classified into three main groups (Figure 11) (100): 
§ Reflex (neurally mediated) syncope – including vasovagal-, situational-, carotid sinus 
syndrome and non-classic forms of syncope. The common denominator in this group 
is the fact that the autonomic reflexes controlling circulation are intact but 
hyperreactive, and respond inappropriately to a stimulus, involving sympathetic 
withdrawal or unopposed vagal tone. This causes an inadequate decrease in peripheral 
resistance or heart rate. 
§ Orthostatic syncope – syncope due to orthostatic hypotension is defined as an 
abnormal decrease in systolic blood pressure upon standing, as opposed to reflex 
syncope, which is caused by impaired autonomic function, i.e. insufficient response 
from the autonomic reflexes. This group includes volume depletion, drug-induced 
orthostatic hypotension and primary or secondary autonomic failure. 
§ Cardiac (cardiovascular) syncope – syncope due to arrhythmias or structural 
diseases. Structural diseases can be cardiac, such as acute myocardial ischaemia, 
valve diseases, hypertrophic cardiomyopathy and pericardial diseases. Alternatively, 
they can be extracardiac diseases such as pulmonary embolism and acute aortic 
dissection. Arrhythmias include brady- and tachyarrhythmias, as well as drug-induced 
brady- and tachyarrhythmias.   
3.5.3 Prevalence and prognosis for different types of syncope 
Reflex syncope accounts for almost two-thirds of all syncope episodes, whereas arrhythmic 
and structural cardiovascular aetiologies account for the minority (101). Orthostatic syncope 
is rare before the age of 40 years (100), and the prevalence of bradyarrhythmia and 
tachyarrhythmia increases with age (102). 
The prognosis is related both to underlying comorbidities and to aetiology. Patients with 
cardiac syncope or unknown aetiology have the highest incidence of recurrence, and patients 
with recurrence in turn, are at increased risk of subsequent death and major adverse 







significantly higher mortality than syncope with non-cardiac causes, and annual mortality is 
reported to reach between 18% and 33% (104).  
 
Figure 11. The classification of syncope based on underlying pathophysiology. ANF, 
autonomic failure; ANS, autonomic nervous system; BP, blood pressure. Reprinted with 
permission from “2018 ESC guidelines for the diagnosis and management of syncope” by 
Brignole M, Moya A, de Lange F, et al., 2018. European Heart Journal, 39, 1883-1948. 









3.6 THE IMPLANTABLE LOOP RECORDER IN EVALUATING SYNCOPE 
3.6.1 Initial evaluation and risk stratification of syncope patients 
Syncope is often a diagnostic challenge, due to its infrequent and unpredictable nature. An 
initial diagnostic workup is imperative, consisting of medical history, ECG, and physical 
examination including orthostatic blood pressure measurements. This is able to explain the 
cause of syncope in 23-50% of patients (105, 106).  
If the cause of syncope remains uncertain after the initial evaluation, the next step involves 
risk stratification to identify patients with high-risk features which indicate increased risk of 
major cardiovascular events or sudden cardiac death. Examples of high-risk features include a 
syncope event associated with chest discomfort or palpitations, syncope during exertion or 
supine, and abnormal physical examination or ECG. Additional high-risk features include 
known structural heart diseases and a family history of sudden cardiac death (100). The 
presence of high-risk features informs decisions about whether the patient can be discharged 
and seen in an out-patient clinic, or whether admission for monitoring and diagnosis is 
warranted.  
3.6.2 The role of non-invasive electrocardiogram monitoring in syncope  
The gold standard involves recording cardiovascular parameters during a spontaneous event, 
e.g. symptom versus ECG correlation (107), and the likelihood of establishing a symptom-
ECG correlation increases with longer monitoring times. There are several different 
ambulatory modalities to enable long-term ECG monitoring. The most common initial 
evaluation is short-term telemetry or Holter monitoring for 24-48 hours, but the overall 
diagnostic yield of Holter monitoring is low. In patients with syncope or presyncope, Linzer 
et al. reported a 4% correlation between ECG and symptoms with Holter monitoring for more 
than 12 hours (108). Another option for non-invasive long-term ECG monitoring is an 
external loop recorder which continuously monitors and stores ECG data with a 4 to18-
minute memory buffer. When symptoms appear, the patient activates the device, which stores 
the previous 3-14 minutes and the following 1-4 minutes of recorded information (109). The 
device can also store recordings automatically according to specific predefined criteria for 
brady- or tachyarrhythmia. The ECG recordings can subsequently be uploaded and analysed. 
This system allows monitoring time to extend to months, but long-term compliance is 
challenging because of skin-related problems. The diagnostic yield for external loop 
recorders in syncope patients ranged from 24-36% in two studies with a monitoring time of 







3.6.3 Efficacy and diagnostic yield of the implantable loop recorder in 
syncope patients 
The ILR permits prolonged ECG monitoring without external electrodes, and is an appealing 
alternative for long-term ECG monitoring in patients with infrequent recurrent syncope. A 
considerable number of studies have investigated and documented the clinical use of an ILR 
in syncope patients (Table 3) (112-118).  
The driving factor in terms of the clinical utility and high diagnostic yield reported for the 
ILR in patients with unexplained syncope involves a combination of the elusive nature of 
syncope with infrequent and unpredictable recurrences, and the opportunity for prolonged 
monitoring with an ILR. Furukawa et al. have reported the importance of the duration of 
monitoring, and the fact that the diagnostic yield increases with increased monitoring time. 
They estimated cumulative diagnostic rates of 30% ,43% ,52% and 80% after one, two, three 
and four years of monitoring time respectively (119). 
The ILR has also been shown to be more cost-effective than conventional testing in 







Table 3. Studies on the clinical use of an ILR in patients with syncope. 
 Krahn et al. (112) Krahn et al. (113) ISSUE (114) ISSUE (114) ISSUE (115) ISSUE (116) PICTURE (117) PICTURE (118) 
n 16 60 82 29 52 35 570 514 
Men 12 33 45 11 43 31 264 241 
Mean age 57±19 66±14 63±17 64±15 71±8 66±13 61±17 61±18 
Study 
design 
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Syncope in 94% 
(15/16).  
Diagnosis in 52% 
(14/27) in ILR 
group vs 20% 
(6/30) in 
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78% (170/218).  
Syncope 32% 
(41/128) vs 36% 
(139/386). ILR-
guided diagnosis 






9 patients. 11 patients in ILR 
group. 
4 patients in 
conventional 
group. 





128 patients. 90% vs 79%. 
AECG, ambulatory ECG; BBB, bundle branch block; CSM, carotid sinus massage; ECG, electrocardiogram; ELR, external loop recorder; EPS, 
electrophysiology study; eval., evaluation; excl., exclusion; h, hour; HD, heart disease; ILR, implantable loop recorder; IQ, interquartile range; ISSUE-1, 
The International Study on Syncope of Uncertain Etiology; LVEF, left ventricular ejection fraction; med., median; neg., negative; PC, prospective cohort 
study; PBPT, postural blood pressure test; PICTURE, Place of Reveal In the Care pathway and Treatment of patients with Unexplained Recurrent 







3.6.4 Current recommendations for the use of an implantable loop recorder 
in syncope 
With the publication of the 2009 ESC Syncope guidelines (122), the ILR gained a more 
prominent position in terms of evaluating syncope, and in the 2018 edition of the ESC 
Syncope guidelines, an ILR is recommended for evaluating syncope in the early phase in 
patients who are not high risk (class I), or after comprehensive workup in high-risk patients 
(class I). Furthermore, an ILR should be considered in patients with suspected or confirmed 
reflex syncope, who are presenting with frequent or severe syncopal episodes (class IIa). It 
can also be considered in patients where epilepsy is suspected but treatment has proved 
ineffective (class IIb), as well as in patients with unexplained falls (class IIb) (100). In the 
ACC/AHA/HRS 2017 Syncope guidelines, an ILR is recommended (class IIa) in patients 
with recurrent, unexplained syncope with a suspected arrhythmic cause, after a non-
diagnostic initial workup, regardless of the presence of structural heart disease (123). 
3.6.5 Baseline 12-lead electrocardiogram  
Few studies have investigated the relationship between baseline 12-lead ECG and the 
syncope mechanism. The above-mentioned ISSUE-1 (International Study on Syncope of 
Uncertain Etiology) study reported an incidence of 32% (22/52 had syncope recurrence, 17 
due to complete heart block) of syncope due to complete heart block in patients with bundle 
branch block (113). A study conducted by Kadmon et al. found a positive predictive value 
(PPV) of 56.3% (9/16) for conduction abnormalities (including long PR interval and bundle 
branch block) in predicting a diagnosis of bradyarrhythmia (124).  
Two studies have examined the use of empiric permanent pacing in patients with bifascicular 
block and syncope. In the SPRITELY trial (Syncope: Pacing or Recording In ThE Later 
Years, NCT01423994), a strategy with empiric permanent pacing was compared to 
implanting an ILR in older patients. The study design was published in 2012 (125) and the 
study completion date was 1st November 2017, but the results have not yet been published. 
However, preliminary results have been presented, and with a strategy involving direct 
permeant pacing they reveal a reduced rate of major adverse events, but the same rate of 
recurrence of syncope (126). The second study was a prospective cohort study, and compared 
empiric permanent pacing to a treatment strategy based on the results of an electrophysiology 
study. The researchers found a high incidence of advanced atrioventricular (AV) block during 
follow-up. They also found no additional benefit for treatment based on an electrophysiology 







Both European and American Pacing guidelines stress the importance of using available 
diagnostic tests, e.g. external and internal loop recorders, to reach a diagnosis before 
implanting a pacemaker (128, 129). One reason for this recommendation is that a significant 
proportion (38%) of patients with bundle branch block and unexplained syncope have 
syncope spells for reasons other than complete heart block (130), e.g. ventricular arrythmias 
or non-arrhythmic causes. Another reason is that, compared to inactive cardiac pacing, active 
pacing mainly improves symptoms. Only a very small proportion (14%) of patients benefit 
from pacing because of actual bradyarrhythmia (131). If positive electrophysiology study 
permanent pacing is indicated, but if the electrophysiology study is inconclusive, an ILR is 
preferred, and permanent pacing has a class II indication (128, 129). However, the ESC 2013 
Cardiac pacing guidelines leave an opening for the physician to carry out an individual cost-
benefit evaluation for selected patients, especially for older patients with recurrent 
unpredictable syncope episodes without prodromes (128).  
3.7 POSTOPERATIVE ATRIAL FIBRILLATION 
3.7.1 Incidence and pathophysiology of postoperative atrial fibrillation 
New-onset postoperative AF is common, and develops in about 3% of unselected patients 
undergoing non-cardiac surgery (132). It affects approximately one-third after cardiac surgery 
(133-137). Typically, it occurs on the second or third postoperative day, and converts 
spontaneously to sinus rhythm within 24-48 hours (133).  
The pathophysiology of postoperative AF is probably multifactorial, with contributing factors 
such as activation of the sympathetic system, hypovolemia, anaemia, trauma and 
interoperative hypotension. Additional factors are metabolic imbalance (e.g. electrolyte 
disturbances or hypoglycaemia), hypoxia and hypervolemia (138). Furthermore, systemic 
inflammation can play a role (139), and for cardiac surgery significant lesions in the coronary 
arteries supplying right and left atria are an independent predictor (i.e. atrial ischaemia), as 
well as direct injury to the atrial myocardium (133). 
Risk factors for postoperative AF include advanced age, male gender, history of congestive 
heart failure, increased extent of operation and elevated B-type natriuretic peptide (BNP), 
obesity, metabolic syndrome, chronic obstructive pulmonary disease, history of AF, valvular 
surgery and the withdrawal of beta blockers or angiotensin-converting enzyme inhibitors 








3.7.2 Short and long-term risks of postoperative atrial fibrillation  
In both a short and long-term perspective, postoperative AF is associated with increased risk 
of complications. Short-term complications include higher risk of ischaemic stroke and 
myocardial infarction, longer length of hospital stay and increased in-hospital mortality (134, 
143). In the long term, postoperative AF is associated with increased risk of future AF, 
ischaemic stroke and cardiovascular mortality (144-150). According to a meta-analysis 
including six studies, the incidence rate of AF recurrence after discharge with non-invasive 
monitoring in the first month was 28.3% (95%CI 23.0-33.6%). In addition, two studies with 
implantable devices report an AF recurrence rate of 60.9% and 100% respectively (151-153). 
A study by Ahlsson et al. showed an eightfold increased risk of developing AF (25.4% versus 
3.6%) and a doubled risk of long-term cardiovascular mortality in patients with postoperative 
AF compared to those who remained in sinus rhythm after aortocoronary bypass surgery 
(146). In terms of postoperative AF after non-cardiac surgery, a recent meta-analysis 
including 28 studies showed a threefold increased risk of stroke and all-cause mortality, and a 
fourfold increased risk of myocardial infarction (154).  
3.7.3 Prevention of postoperative atrial fibrillation  
Beta blockers have been shown to reduce the incidence of postoperative AF (155, 156), as 
well as amiodarone (155, 157). In the AHA/ACC/HRS 2014 AF guidelines, peroperative 
administration of amiodarone to reduce the risk of postoperative AF in high-risk patients has 
a class IIa recommendation (26). The American Association for Thoracic Surgery (AATS) 
published specific guidelines for the prevention and management for postoperative AF in 
2014, and their recommendations involve continuing (i.e. not withdrawing) beta blockers in 
all patients (class I), as well as considering amiodarone administration in intermediate to 
high-risk patients (class IIa) (158). The ESC 2020 AF guidelines give perioperative 
administration of beta blockers or amiodarone a class I indication (20). No other drugs have 
been shown to reduce the incidence of postoperative AF.  
3.7.4 Anticoagulation treatment for postoperative atrial fibrillation 
It is essential to weigh the benefits of OAC treatment for stroke prevention against the risks 
of postoperative bleeding. Current recommendations, from European and American societies, 










Table 4. Recommendations regarding OAC treatment in patients with postoperative AF. 
AHA/ACC/HRS 
(26)  
Reasonable to start OAC treatment in accordance with the 
recommendations for non-surgical patients (class IIa). 
AATS (158) AF ≥48 hours: reasonable to start OAC treatment in accordance with 
the recommendations for non-surgical patients, weighing the 
prevention of stroke against the risk of bleeding (class I). 
AF <48 hours: OAC treatment should be considered based on the 
CHA2DS2-VASc score, but also taking into consideration that the 
presence of impaired renal function weighs in favour of OAC 
treatment (class I). 
Minimum duration of OAC treatment is four weeks after restoration of 
sinus rhythm (class I).  
More prolonged OAC treatment can be beneficial in the presence of 
stroke-risk factors according to the CHA2DS2-VASc score, or if the 
patient has had a previous stroke (class IIa). 
ESC (20) Long-term OAC treatment should be considered in the presence of 
stroke-risk factors, taking individual stroke and bleeding risk into 
consideration (class IIb). 
AATS, American Association for Thoracic Surgery; ACC, American College of Cardiology; 
AF, atrial fibrillation; AHA, American Heart Association; CHA2DS2-VASc, (Congestive heart 
failure, Hypertension, Age >75 years (2 points), Diabetes, Stroke (2 points), Vascular 
disease, Age 65-74 and Sex (female)); ESC, European Society of Cardiology; HRS, Heart 









3.8 THE IMPLANTABLE LOOP RECORDER FOR DETECTING ATRIAL 
FIBRILLATION 
3.8.1 Performance of the implantable loop recorder in detecting atrial 
fibrillation 
Modern ILRs are equipped with an automatic algorithm for AF detection, and all 
manufacturers base the algorithm on the identification of QRS signals and analyses of the RR 
interval stability. If a predefined pattern of variability is identified, the heart rate is classified 
as AF (91). These algorithms have been validated using continuous Holter monitoring as the 
gold standard. The sensitivity for detecting AF ranged from 96-100%, while the specificity 
ranged from 67-86%. When all AF episodes were considered, the sensitivity was somewhat 
lower, at 88-95% (42, 159, 160). In terms of AF detection rate, an ILR is superior to all other 
modalities (161, 162), and in the LOOP (Atrial Fibrillation Detected by Continuous ECG 
Monitoring, NCT02036450) study the detection rate was highest in the elderly, males and 
those who had high N-terminal-prohormone BNP levels (162).  
Manufacturers are constantly trying to improve the performance of their AF-detection 
algorithms. One vendor has further developed its AF-detection algorithm by checking the 
presence of P-waves once the RR variability exceeds the threshold for AF detection (163, 
164). Recently, this manufacturer further refined the P-sense algorithm, reaching a sensitivity 
of 100% for AF episodes ≥2 minutes in duration with a PPV of 97% (165). Another vendor 
has enhanced its detection by redesigning its device to enable a very long sensing vector, 
resulting in a sensitivity of 97% for AF episodes ≥6 minutes’ duration and a PPV of 72.5% 
(166). 








4 AIMS  
4.1 OVERALL AIM 
Cardiac implantable electronic devices (CIEDs) enable continuous monitoring of the heart 
rhythm, and as the duration of cardiac monitoring is of the utmost importance for the 
detection rate of arrhythmias, CIEDs constitute a unique opportunity for arrhythmia 
detection. Nevertheless, it is often difficult to know how to manage all the information from 
device diagnostics, and how it should influence clinical decisions. 
This thesis aims to highlight different aspects of arrhythmias diagnosed with CIEDs from 
both a diagnostic and therapeutic point of view, with an emphasis on diagnosis of syncope 
and detection of subclinical AF/AHREs, aimed at preventing strokes. 
4.2 STUDY I 
To describe the incidence of subclinical AF/AHREs in a population of patients implanted 
with a dual-chamber pacemaker, as well as to describe their OAC treatment and incidence of 
ischaemic stroke and vascular dementia.  
4.3 STUDY II 
To evaluate the role of baseline 12-lead ECG in predicting the syncope mechanism during 
continuous ECG monitoring with an ILR in a consecutive group of patients with unexplained 
syncope, selected to receive an ILR after the initial syncope investigation was non-diagnostic.   
4.4 STUDY III 
To study the role of age and gender in the evaluation before implanting an ILR, and in the 
subsequent diagnostic yield of the ILR, in a population of patients selected to receive an ILR 
after the initial investigation had failed to disclose the syncope mechanism.   
4.5 STUDY IV 
The primary aim was to test the hypothesis that patients with incident AF during inpatient 
care after coronary artery bypass graft (CABG) surgery often relapse into AF within a year, 









5 PATIENTS AND METHODS 
5.1 STUDY I 
This was an observational cohort study including consecutive patients implanted with a dual-
chamber pacemaker or cardiac resynchronisation therapy pacemaker, during the period 2010-
2014 in Halland County in Sweden. The device indications were sinus node disease or AV 
block/bundle branch block. For the study flowchart, see Figure 12. 
 
Figure 12. Flowchart of the study design for study I. AF, atrial fibrillation; AHRE, atrial 
high-rate episode; ICD, implantable cardioverter defibrillator. Reprinted with permission 
from “Stroke incidence and anticoagulation treatment in patients with pacemaker-detected 
silent atrial fibrillation” by Sandgren E, Rorsman C, Edvardsson N, et al., 2018. PLoS One, 
13, e020366 (https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6136732). Copyright © 2018, 








Medical records were used to retrieve clinical data, and protocols from the pacemaker 
interrogations were used to retrieve information about the occurrence of subclinical 
AF/AHREs. AF was confirmed when an episode of at least five minutes was captured by an 
AF-detection algorithm, or captured as an AHRE supported by a stored rhythm strip available 
for adjudication. AHREs which were not supported by a rhythm strip were simply called 
AHREs. For patients with no clinical/known AF, subsequent initiation of OAC treatment was 
noted, and for patients with clinical/known AF, ongoing OAC treatment and any changes in 
this treatment were noted. Follow-up lasted until the end of 2015 for the detection of 
subclinical AF/AHREs and until the end of 2017 for the incidence of ischaemic stroke and 
vascular dementia. Information about the incidence of ischaemic stroke and vascular 
dementia was obtained from the Regional Patient Register.  
5.2 STUDIES II AND III 
These two observational studies are based on the same patient cohort, including consecutive 
patients with unexplained syncope during the period 2007-2016, who were selected to receive 
an ILR after an initial non-diagnostic evaluation at one of two hospitals in Halland County in 
Sweden. Patients did not proceed to ILR implantation if there was a positive diagnostic 
evaluation, and therefore our patient population comprised a selected portion of the syncope 
population. Flowcharts for studies II and III are shown in Figures 13 and 14 respectively. 
Clinical data and baseline 12-lead ECG were retrieved through medical records. Baseline 12-
lead ECG was adjudicated (ES, NE, JE) and classified according to recommendations for 
ECG findings suggestive of arrhythmic syncope in the ESC 2018 Syncope guidelines (100). 
If disagreement, a second assessment was performed to reach consensus (was required for 
five ECGs). Bifascicular block included findings of left bundle branch block (LBBB) or right 
bundle branch block (RBBB) plus left anterior hemiblock (LAH) or left posterior hemiblock 
(LPH). AV block I was defined as PR interval ≥200 milliseconds.  
The ILRs automatically stored the following events: pauses >3 seconds, bradycardia <30 bpm 
during at least four beats, and tachycardia >176 bpm during at least 16 beats. An AF-
detection algorithm was activated if available.  
To confirm the underlying syncope mechanism, an ECG recording during recurrent syncope 
was required. If the ECG recording captured an arrhythmia, diagnosis was arrhythmic 
syncope, and if the ECG recording was normal it was non-arrhythmic syncope. Presyncope 
was considered non-diagnostic, and asymptomatic ECG findings highly suggestive of 
arrhythmic syncope (AV block II:II or III, persistent bradycardia or ventricular pauses >3 







(100) were considered to be potentially diagnostic of the syncope mechanism. All ECG 
recordings were reviewed by at least one cardiologist.  
 
Figure 13. Flowchart of the study design for study II. ECG, electrocardiogram; ILR, 
implantable loop recorder; ms, millisecond. Reprinted with permission from “Role of 
baseline 12-lead ECG in predicting syncope caused by arrhythmia in patients investigated 
using an implantable loop recorder” by Sandgren E, Rorsman C, Edvardsson N, et al., 2019. 
International Journal of Cardiology Heart & Vasculature, 24, 100386 
(https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6603332/). Copyright © 2019, The Authors. 








It is worth noting the difference between the two terms ILR-guided diagnosis and ECG-based 
diagnosis, used in the results section for studies II and III respectively. ILR-guided diagnosis 
(study II) includes all patients where the ILR has informed the clinical diagnosis, i.e. where 
captured ECG recordings both during syncope recurrence or other times have enabled a 
clinical diagnosis to be made. ECG-based diagnosis (study III) only includes those with 
recurrence of syncope. 
Follow-up lasted until a mechanism of syncope was revealed or the battery expired.  
 
 
Figure 14. Flowchart of the study design for study III. ECG, electrocardiogram; ILR, 
implantable loop recorder.  
5.3 STUDY IV 
This was a sub-study of the prospective AFAF study (Atrial Fibrillation AFter CABG and 
percutaneous coronary intervention). The AFAF study investigates the incidence of AF after 
percutaneous coronary intervention or CABG surgery. Non-invasive handheld ECG 
recordings are conducted three times daily during the first postoperative month, and for two 
weeks at three, 12 and 24 months in addition to routine care. The patients were instructed to 
perform ECG recordings at the same times every day, and in case of symptoms. Each ECG 
recording was 30 seconds.  
In addition to the handheld ECG, this sub-study included continuous ECG monitoring with 
an ILR. The ILR was implanted during the CABG surgery, and data collection and remote 







tachyarrhythmias according to predefined criteria (bradyarrhythmia <30 bpm for at least four 
beats and pause >3 seconds; tachyarrhythmia >176 bpm for at least 16 beats), and an 
investigator checked the ILR data weekly via the remote monitoring system. False positive 
strips were excluded by manual adjudication.  
Clinical data, echocardiographic measurements and information about medications were 
retrieved from medical records, as well as from digital report forms completed by phone at 
baseline and after one, three, and 12-months of follow-up within the AFAF study. To 
diagnose AF during the in-hospital stay at least a 30-seconds telemetry recording or a 12-lead 
ECG was required.  
Exclusion criteria involved a history of AF, pacemaker treatment or other non-sinus rhythm, 
bleeding disorder where OAC treatment was contraindicated, cognitive impairment or 
communication problems leading to difficulties in taking instructions and completing the 
written informed consent form, malignancy or other diseases with life expectancy less than 
one year and ongoing anticoagulation treatment.  
5.3.1 Outcome measures  
The primary endpoint of the study was the proportion of patients diagnosed with incident or 
recurrent AF during the 12-month follow-up. The secondary endpoint was the AF burden, i.e. 
the total time in AF calculated from all AF recordings with at least two minutes duration.  
Any other significant arrhythmias were recorded as exploratory variables, e.g. atrial flutter or 










Descriptive statistical analysis was used in studies I-IV. Continuous variables were reported 
as mean and standard deviation (SD), median and range, median and interquartile range 
(IQR), median with 25th and 75th percentiles and minimum and maximum value or 95% 
confidence interval (CI). Categorial variables were reported as frequencies and percentages. 
Univariate analysis of the continuous variables was performed using the independent samples 
T-test, or if assumptions were not met, the non-parametric Mann-Whitney U test. A one-way 
analysis of variance (ANOVA) was used to compare means of more than two groups. For 
categorical variables, Fisher’s exact test or chi-squared test were used. All tests were two-
sided with a significance threshold of p< .05. 
Kaplan-Meier curves were used in studies I-II. In study I, these were used to illustrate time 
from pacemaker implantation to first episode with subclinical AF/AHRE, and time from 
pacemaker implantation to subclinical AF/AHRE diagnosis. In study II, they were used to 
describe time to clinical diagnosis separately for those with bifascicular block, AV block I or 
normal baseline 12-lead ECG. The non-parametric log rank (Mantel Cox) test was used for 
statistical comparison. 
Positive and negative predictive values were calculated in study II to describe the 
performance of bifascicular block in predicting a clinically adjudicated arrhythmia-caused 
syncope. 
Multivariate logistic regression was used in studies II-IV. In study II, it was applied twice, to 
calculate the adjusted odds ratios for risk factors for a clinically adjudicated arrhythmia-
caused syncope, and in the entire population to calculate the adjusted odds ratios for baseline 
12-lead ECG findings predictive of a clinically adjudicated arrhythmia-caused syncope due to 
bradyarrhythmia. In study III it was used to evaluate the impact of age, gender and the 
number of pre-implant diagnostic tests on the outcome of an ECG-based diagnosis and a 
diagnosis of arrhythmic syncope. Finally, in study IV multivariate analysis was used to 
calculate the adjusted odds ratios for variables predicting the occurrence of AF during the 12-
month follow-up after CABG surgery. In study IV, the Cox and Snell R2 and the Nagelkerke 
R2 values provided an indication of the amount of variation in the dependent variable 
explained by the model. The Enter method was used for all analyses, and variables with a 
probability value of less than 0.1 were included in the final model. Collinearity diagnostics 







Data processing and analyses were carried out using Microsoft Excel and IBM SPSS version 
24-27. 
5.4.2 Power calculations 
Studies I-III were cohort studies, and the sample size was limited to the available cohorts. CI 
were calculated for primary outcomes. Study IV was a pilot study intended to investigate the 
feasibility of ILR diagnostics after CABG surgery. Data from this study will form the basis 
for power calculations for future studies.  
5.5 ETHICAL CONSIDERATIONS 
All four studies conform to the ethical principles of the 1975 Declaration of Helsinki, and 
have been approved by the Regional Ethical Review Board in Lund (study I: Dnr 2015/648, 
studies II and III: Dnr 2014/653) and Uppsala (study IV: Dnr 2015/413).  
Studies I-III were observational cohort studies, and patient consent for these studies was 
obtained through an opt-out procedure. Due to their retrospective design, they did not involve 
any physical risks and did not affect the participants’ treatment. However, the studies could 
have caused anxiety and injury due to violation of integrity as a result of collecting patient 
data outside the scope of ordinary medical care. To prevent harm to the patients’ integrity, all 
personal data were processed in accordance with applicable privacy laws and were stored in 
the principal’s network, so that they were only available to the investigator.  
Study IV was prospective, and patient consent was obtained in written form before 
enrolment. The privacy violation was considered exiguous, as sensitive personal data were 
collected only after informed consent was given. All patients had an ILR inserted, and this 
could potentially have caused discomfort and infection at the site of surgery. The patients 
were informed that the ILR could be removed at any time. Patients who have undergone 
CABG surgery are at increased risk of developing AF and the potential benefits of finding a 
treatable AF were considered greater than the risks associated with minor surgery. 
Accordingly, the study meant that patients diagnosed with AF were assessed and offered 
OAC treatment according to the guidelines. The potential benefit for the participant, i.e. being 
offered OAC treatment, was considered greater than the potential inconvenience of 








6.1 STUDY I 
Mean follow-up time was 38±17 months for the detection of subclinical AF/AHREs, and 
65±17 months for the ischaemic stroke and vascular dementia diagnosis. In total, 694 patients 
were enrolled (395 men). At the time of pacemaker implantation 271 patients had 
clinical/known AF and their median CHA2DS2-VASc score was 4 (IQR 2), while the 423 
patients with no AF diagnosis had a score of 3 (IQR 2), p= .003. (Baseline data Table 5 and 
6). Of patients with clinical/known AF, 38% (102/267) had died at the end of follow-up 
compared to 29% (121/411) of patients with no clinical/known AF at implantation, p= .02. 
Table 5. Patient demographics at implantation for those with and without subclinical 
AF/AHREs during follow-up. 
 AHREs, n=125 No AHREs, n=286 p-value 
Age  79.0±8 73.3±11 <0.001 
<50 years 0(0%) 14(5%) .001 
50-65 years 7(6%) 45(16%) 
 
>65 years  118(94%) 227(79%) 
 
CHA2DS2-VASc 3(2.5-4, 0-7) 3(2-4, 0-7) .01 
Congestive heart failure 12(10%) 11(4%) .04 
Hypertension 80(64%) 157(55%) .10 
Diabetes 19(15%) 55(19%) .40. 
History of ischaemic stroke 15(12%) 34(12%) .76. 
Vascular disease 38(30%) 63(22%) .08 
    
Sinus node disease* 29(23%) 76(27%) .54 
AV block I-III/ bundle branch block** 95(76%) 199(70%) .19 
Sinus node disease  + AV block I-III 1(0.8%) 6(2.1%) .68 
Vagal reaction 0(0%) 1(0.4%) 1.0 
Tachy-brady syndrome  0(0%) 4(1.4%) .32 
*Exclusive tachy-brady syndrome. **Including bifascicular block + syncope (n=2) and 
trifascicular block (n=6). Reported values are mean±SD, median (25th-75th percentiles and 
minimum-maximum value) or n (%). AF, atrial fibrillation; AHRE, atrial high-rate episode; 
AV, atrioventricular; CHA2DS2-VASc, (Congestive heart failure, Hypertension, Age >75 
years (2 points), Diabetes, Stroke (2 points), Vascular disease, Age 65-74 and Sex (female)); 
IQR, interquartile range; SD, standard deviation. Statistical tests used: independent samples 
T-test, ANOVA (analysis of variance), non-parametric Mann-Whitney U test, chi-squared test 







Table 6. Distribution of the components of the CHA2DS2-VASc score at implantation.  
 
C n (%) H n (%) A n (%) D n (%) S n (%) V n (%) A n (%) Sc n (%) 
All patients, n=694 37(5.3) 430(62) 433(62) 119(17) 92(13) 197(28) 188(27) 297(43) 
Known AF at implantation, n=271 13(4.8) 186(69) 189(70) 43(16) 40(15) 93(34) 69(25) 136(50) 
AF not known at implantation, n=423 24(5.7) 244(58) 244(58)  76(18) 52(12) 104(25) 119(28) 161(38) 
p-value  .73  .004  .002  .54  .36  .006  .48  .002 
AHREs during FU, n=125 12(9.6) 80(64) 89(71) 19(15) 15(12) 38(30) 31(25) 40(32) 
Free of AHREs during FU, n=286 11(3.8) 157(55) 147(51) 55(19) 34(12) 63(22) 86(30) 115(40) 
p-value  .03  .10  .0002  .40 1.00  .08  .29  .12 
AF, atrial fibrillation; AHRE, atrial high-rate episode; CHA2DS2-VASc, (Congestive heart failure, Hypertension, Age >75 years (2 points), Diabetes, 







Of 411 patients with no clinical/known AF at implantation, 125 were diagnosed with 
subclinical AF/AHREs during follow-up. AF diagnosis was verified in 61 patients (stored 
EGM: 59; 12-lead ECG: 2), and the diagnosis was based solely on AHREs in 64 patients 
(only one patient had AHREs which lasted less than one hour). Seven patients reported 
symptoms. The median time from implantation to the first episode of subclinical AF/AHRE 
and from the first episode to confirmation was seven (range 0.1-62) months and five (range 0-
28) months respectively. Two-thirds (79/125) of the patients had their first episode during the 
first year of monitoring, and one-third (44/125) within the first three months. Patients with 
incident subclinical AF/AHREs during follow-up were older (AHRE: 79±8 years; no AHRE: 
73.3±11 years; p< .001) and more often had congestive heart failure (AHRE: 12/125, 10%; 
no AHRE: 11/286, 4%; p= .04).  
At implantation, 80% (216/271) of patients with clinical/known AF were on OAC treatment. 
Of the 125 patients diagnosed with subclinical AF/AHREs during follow-up, almost two-
thirds received OAC treatment (six patients had OAC treatment for reasons other than AF; 72 
were prescribed OAC treatment). 
The annual stroke incidence was as follows: 2.1% in patients with clinical/known AF at 
implantation, 1.9% in patients with incident subclinical AF/AHREs and 1.4% in patients with 
no subclinical AF/AHREs. Divided by duration of the episode with subclinical AF/AHRE, 
patients with episodes shorter than 5.5 hours (72/125, 58%) had a total ischaemic stroke 
incidence of 9.7% and an annual incidence of 1.5%, and the corresponding numbers for 
patients with episodes longer than 5.5 hours (53/125, 53%) were 11.3% and 1.0% 
respectively.  
The incidence of vascular dementia during follow-up was 11.2% (30/267) for patients with 
clinical/known AF at implantation, 5.6% (7/125) in patients with incident subclinical 
AF/AHREs, p= .09, and 6.2% (18/286) in patients without subclinical AF/AHREs, p= .048. 













Table 7. Ischaemic stroke and vascular dementia incidence during follow-up, indicated 







No AHREs,  
n=286 
Number of ischaemic strokes 31 13 20 
Total incidence 11.0% 10.0% 7.0% 
Annual incidence 2.1% 1.9% 1.4% 
OAC treatment (total/ with stroke) 216/23 78/5 -/3 
    
Vascular dementia 30 7 18 
Total incidence 11.2% 5.6% 6.2% 
Annual incidence 2.1% 1.0% 1.2% 
AF, atrial fibrillation; AHRE, atrial high-rate episode; OAC, oral anticoagulation. 
6.2 STUDY II 
The study population consisted of 300 patients, as one patient declined to participate. Half of 
the study population consisted of women (n=147, 49%) and the mean age was 66±16.5 years. 
Two hundred eighty-eight received the ILR due to syncope, and 12 due to presyncope. Mean 
follow-up time was 21±15.4 (median 19, range 0.25-60) months, and mean time to receiving 
an ILR-guided diagnosis 11±10.8 (median 7, range 0.25-42) months. 
At baseline, the most common pathological 12-lead ECG findings were bifascicular block 
(n=33) and AV block I (n=48). Patients with bifascicular block were distributed as follows: 
24 LBBB, eight RBBB + LAH and one RBBB + LPH. Baseline 12-lead ECG findings are 
reported in Table 8, and results are indicated separately for patients clinically adjudicated to 
have an arrhythmia-caused syncope, non-arrhythmia-caused syncope and no ILR-guided 












Table 8. Baseline 12-lead ECG findings, indicated separately for patients clinically 
adjudicated to have an arrhythmia-caused syncope, non-arrhythmia-caused syncope and no 








Bifascicular block 24 1 8 
QRS >120 ms 7 1 5 
Sinus bradycardia <50 bpm 4 1 3 
Sinus tachycardia 0 0 0 
Ventricular tachycardia 0 0 1 
Preexcitation 0 0 0 
Long QT 0 2 1 
Q-waves 3 1 6 
Early repolarisation 0 4 1 
AV block I 21 5 22 
None of above ECG findings   54 36 115 
26 patients had more than one ECG abnormality. AV, atrioventricular; bpm, beats per 
minute; ECG, electrocardiogram; ILR, implantable loop recorder; ms, millisecond.  
One hundred forty-six patients (49%) received an ILR-guided diagnosis. Ninety-seven (66%) 
were clinically adjudicated to have an arrhythmia-caused syncope and 49 (33%) to have a 
non-arrhythmia-caused syncope. Of patients clinically adjudicated to have an arrhythmia-
caused syncope, 76% (74/97) of cases had an ECG recording of a bradyarrhythmia and 24% 
(23/97) an ECG recording of a tachyarrhythmia.  
Patients with pathological findings at baseline 12-lead ECG more often received an ILR-
guided diagnosis and were more often clinically adjudicated to have an underlying 
arrhythmia as the cause of syncope compared to those with a normal baseline 12-lead ECG: 
59% (56/95) vs 44% (90/205), p= .018, and 45% (43/95) vs 26% (54/205), p= .001 
respectively. The highest incidence of ILR-guided diagnosis at 76% (25/33) and clinically 
adjudicated arrhythmia-caused syncope at 96% (24/25) was in patients with bifascicular 
block at baseline 12-lead ECG. Of these patients, 23 had an ECG recording of a 
bradyarrhythmia (intermittent complete heart block:19, sinus pauses: three, and sinus 
bradycardia: one) and one had an ECG recording of a tachyarrhythmia (atrioventricular nodal 
re-entrant tachycardia). One patient with bifascicular block was clinically adjudicated to have 








In particular, bifascicular block was common in patients over 60 years of age (94%, 31 out of 
33 patients). Bifascicular block was a strong predictor of a clinically adjudicated arrhythmia-
caused syncope, with an adjusted odds ratio of 5.5 (95%CI 2.3-13.2), p< .001, and a PPV of 
73%. In the total population, bifascicular block predicted a clinically adjudicated arrhythmia-
caused syncope due to bradyarrhythmia, with an adjusted odds ratio of 11.4 (95%CI 5.0-
26.2), p< .001.  
Patients with bifascicular block had significantly shorter time to ILR-guided diagnosis than 
those with AV block I and normal baseline 12-lead ECG (Figure 15).  
 
Figure 15. Kaplan-Meier curve illustrating time to clinical diagnosis, separated according to 
those with bifascicular block (median three months, range 0.25-30), AV block I (median 
seven months, range 1-34) or normal baseline 12-lead ECG (median nine months, range 
0.25-42), p= .004. AV, atrioventricular; ECG, electrocardiogram. Statistical test used: Log 
rank (Mantel Cox). Reprinted with permission from “Role of baseline 12-lead ECG in 
predicting syncope caused by arrhythmia in patients investigated using an implantable loop 
recorder” by Sandgren E, Rorsman C, Edvardsson N, et al., 2019. International Journal of 
Cardiology Heart & Vasculature, 24, 100386 
(https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6603332/). Copyright © 2019, The Authors. 







6.3 STUDY III 
Three hundred patients were included, and their age and gender distribution are visualised in 
Figure 16. At baseline, men more often had AV block I (men: 35/153, 23%; women: 13/147, 
9%; p< .001), and women more often had a normal 12-lead ECG (men: 90/153, 59%; 
women: 115/147, 78%; p< .001).  
 
Figure 16. Of 300 patients, 9% of patients were younger than 40 years of age, 20% were 
between 40 and 59 years of age, and 71% of patients were ≥60 years of age. 
Eighty-nine patients had syncope recurrence during follow-up and accordingly received an 
ECG-based diagnosis, which was more common in women than in men (women: 56/147, 
38%; men: 33/153, 22%; p= .001). In 47 patients the underlying cause was an arrhythmia, 
while 42 suffered recurrent syncope with a normal ECG recording, i.e. non-arrhythmic 
syncope; this was most common in women (women: 27/147, 18%; men 15/153, 10%; p= 
.045).  
Syncope recurrence due to arrhythmia was more common in patients ≥60 years of age (<40 
years: 3/11, 27%; 41-59 years: 7/18, 39%; and ≥60 years: 37/60, 62%; p= .045), and 
especially syncope recurrence due to a bradyarrhythmia (<40 years: 1/11, 9%; 40-59 years: 








Figure 17. ECG, electrocardiogram.  
In another three patients, the recurrent event turned out to be a seizure, which was suggested 
according to tonic-clonic activity in ECG recordings. 
Fifty patients with no recurrent syncope (42 with presyncope and eight with no symptoms) 
had ECG recordings which may be indicative of arrhythmic syncope according to the ESC 
2018 Syncope guidelines (100), with no gender or age difference (Figure 18). Another 20 
asymptomatic patients, three-quarters of whom were men (women: 5; men: 15; p= .04), had 
an ECG recording involving other arrhythmias. 
For the total number of diagnostic tests upfront ILR implantation, there were no gender 
differences, but there was an age difference, as patients ≥60 years of age underwent fewer 
diagnostic tests upfront ILR implantation (<40 years: 6.5±1.2; 40-59 years: 5.75±1.0; and 
≥60 years: 5.1±1.9; p= .002). However, broken down into the different tests, women more 
often underwent ambulatory ECG monitoring (women: 79/147, 54%; men: 60/152, 39%; p= 
.015) and myocardial scintigraphy (women: 7/147, 5%; men: 0/152, 0%; p= .0006), while 
men were more often hospitalised for ECG monitoring (women: 89/147, 61%; men: 111/152, 
73%; p= .037) and referred for cardiac magnetic resonance imaging (women: 16/147, 11%; 
men: 26/152, 17%; p= .027). The total number of pre-implant tests did not impact the 








Figure 18. ECG, electrocardiogram. 
In a subgroup analysis where patients with presyncope (women: 7; men: 5) as the indication 
were included, no difference was found to the total population regarding mean age and 
number of diagnostic tests upfront ILR implantation. Of these 12 patients, one suffered 
syncope and three presyncope during follow-up. The three patients with presyncope and one 
patient without symptoms had ECG findings which may be indicative of arrhythmic syncope 
according to the ESC 2018 Syncope guidelines (100). Another two patients had 












6.4 STUDY IV 
Thirty-nine men and one woman with a mean age of 68±8 years were included, and all of 
them except two were alive (death occurred three and four months after surgery respectively) 
and followed until the end of the 12-month follow-up. Table 9 shows their baseline 
characteristics, indicated separately for patients with and without AF during follow-up. The 
CHA2DS2-VASc score was higher for patients with AF than for patients who remained in 
sinus rhythm, with median 4 (IQR 1) and median 3 (IQR 2) respectively, p= .006. Mean time 
spent in hospital was 6.7±3 days, range 4-21 days. Two patients suffered peroperative 
complications (pericardial effusion and cardiac ischaemia).  
Table 9. Baseline characteristics in patients with and without AF during 12-month 
monitoring after CABG surgery. 
 No AF AF p-value 
Total number 13 27  
Age 63.6(95%CI 58.2-69.1) 70.4(95%CI 67.7-73.2) .012 
Women 0(0%) 1(3.7%) 1.0 
Body mass index 29.3(95%CI 26.4-32.2) 30.1(95%CI 28.0-32.2) .650 
CHA2DS2-VASc score 3(IQR 2) 4(IQR 1) .006 
Smoking status 
  .200 
Non-smoker 8(62%) 11(40.7%)  
Former (>1 month) 5(38%) 11(40.7%)  
Smoker 0(0%) 5(18.5%)  
Alcohol consumption* 
  .320 
None 1(8%) 3(11.5%)  
<8 units/week 10(84%) 23(88.5%)  
>8 units/week 1(8%) 0(0%)  
Congestive heart failure 1(7.7%) 6(22.2%) .390 
Previous myocardial infarction 3(23%) 16(59.3%) .046 
COPD  0(0%) 0(0%) - 
Obstructive sleep apnoea 1(7.7%) 1(3.7%) 1.0 
Hypertension 7(54%) 22(81.5%) .130 
Diabetes 5(38%) 10(37%) 1.0 
Previous stroke** 0(0%) 4(16%) .240 
Peripheral vascular disease 0(0%) 3(11.1%) .540 
Disease definition  
  .690 







Stable angina 7(54%) 17(63%)  
Non-STEMI 2(15%) 5(18.5%)  
Extent of disease (No of vessels)  
  .540 
1 0(0%) 0(0%)  
2 0(0%) 3(11.1%)  
3 13(100%) 24(88.9%)  
Echocardiography 
   
Left ventricular ejection fraction 53.1(95%CI 47.9-58.2) 50.9(95%CI 45.7-56.1) .600 
Left atrium area*** 18.3(95%CI 15.9-20.7) 20.9(95%CI 18.0-23.7) .063 
*Data is missing for one patient with no AF and one patient with AF. ** Data is missing for 
two patients with AF. *** Data is missing for one patient with no AF and two patients with 
AF. Reported values are n (%). AF, atrial fibrillation; CHA2DS2-VASc, (Congestive heart 
failure, Hypertension, Age >75 years (2 points), Diabetes, Stroke (2 points), Vascular 
disease, Age 65-74 and Sex (female)); CI, confidence interval; CABG, coronary artery 
bypass graft; COPD, chronic obstructive pulmonary disease; IQR, interquartile range; no, 
number; STEMI, ST-elevation myocardial infarction. Statistical tests used: independent 
samples T-test, non-parametric Mann-Whitney U test, chi-squared test and Fisher’s exact 
test.  
Twenty-seven of 40 patients (68%) had incident AF during follow-up. Twenty-one were 
diagnosed during hospitalisation, three during the first month after discharge and a further 
three during months 2-12 of post-discharge monitoring. Three patients developed persistent 
AF: one patient already at discharge as first episode, one patient after nine days as first 
episode, and one patient after seven months after experiencing paroxysmal AF episodes. In 
total, 18/27 patients with incident AF had a recurrence of AF (including the one patient who 
progressed to persistent AF), and 15 of these were within the first 30 postoperative days. The 








Figure 19. In total 27 out of 40 patients had incident AF, and 18 of these also suffered one or 
more recurrences during follow-up. AF, atrial fibrillation. 
Prior to CABG surgery, 33/40 were on beta blocker therapy, 18/21 of them with incident AF 
during postoperative hospitalisation. Seventeen of 21 with incident AF during hospitalisation 
received intravenous amiodarone and all except one were in sinus rhythm at discharge. All 
patients with AF received OAC treatment. Antiarrhythmic treatment was prescribed for three 
patients during the first month (one amiodarone, one amiodarone plus direct current 
cardioversion and one dronedarone). During months 2-12, no new patients were prescribed 
antiarrhythmic drugs.  
Multivariate analyses were used to identify baseline predictors of any AF during the 12-
month follow-up. The four variables age, hypertension, previous myocardial infarction and 
left atrium area were included in the final model, which was statistically significant x2 (4, 
N=37) =16.8, p= .002. It explained 37-51% of the variance and correctly classified 78.4% of 










Table 10. Logistic regression identifying predictors for the likelihood of any AF during the 
12-month monitoring period after CABG surgery. 
 Unadjusted odds ratio (95%CI) Adjusted odds ratio (95%CI) p-value 
Age 1.1(95%CI 1.02-1.24) 1.2(95%CI 1.01-1.36)  .043 
Hypertension 3.8 95%CI 0.88-16.24) 8.4(95%CI 0.95-74.09)  .055 
Previous MI 4.8(95%CI 1.08-21.76) 4.4(95%CI 0.57-33.68)  .155 
Left atrium area 1.2(95%CI 0.98-1.46) 1.2(95%CI 0.91-1.47)  .243 
AF, atrial fibrillation; CABG, coronary artery bypass graft; CI, confidence interval; MI, 
myocardial infarction. Statistical test used: binary logistic regression.  
The ILR identified that 20 patients had episodes of AF during the 12-month post-discharge 
monitoring time, while handheld ECG identified nine of them, p= .001. The ILR was more 
effective at detecting AF in month 1, as well as in months 2-12 (Figure 20). However, one 
patient had two episodes of AF in the first week after discharge, and this was only captured 
by a handheld ECG as the ILR had not been activated. Accordingly, the ILR detected 98% 
(102/104) of all individual AF episodes, while handheld ECG detected 29% (30/104), p< 
.0001.  
 
Figure 20. The detection rate was higher for the ILR than the handheld ECG for month 1 and 
months 2-12: 94% (16/17) versus 47% (8/17), p= .007, and 100% (12/12) versus 33% (4/12), 
p= .001 respectively. AF, atrial fibrillation; ECG, electrocardiogram; ILR, implantable loop 







The ILR, but not handheld ECG, captured asymptomatic arrhythmias in eight patients: one 
patient had non-sustained monomorphic ventricular tachycardia, one had intermittent AV 
block III and six patients had sinus arrest and/or sinus bradycardia.  
The median AF burden was 0.1% (IQR 0.28) or 718 (IQR 1296) minutes (Figure 21). 
Fourteen out of 17 patients with paroxysmal AF had AF episodes with a duration of ≥6 
minutes, and in total AF episodes ≥6 minutes constituted 57% (58/101) of all paroxysmal AF 
episodes. 
 
Figure 21. The AF burden was low in all patients except the three patients in red who 
developed persistent AF, and it gradually decreased during the 12-month follow-up. AF, 













7 GENERAL DISCUSSION 
7.1 MAJOR FINDINGS 
This Ph.D. project aimed to highlight different aspects of device-based arrhythmia diagnoses, 
and the findings can be summarised briefly in three paragraphs.  
First, study I showed that episodes of subclinical AF/AHREs were common in the pacemaker 
population, and were associated with older age and congestive heart failure. The stroke 
incidence was low, but clinical/known AF was associated with an increased risk of vascular 
dementia. 
Second, studies II and III, on ILR monitoring in syncope patients, observed that women 
experienced a recurrence of syncope more often than men, a difference mainly driven by 
higher incidence of syncope with non-arrhythmic cause. Age ≥60 years was associated with 
fewer pre-implant tests, but higher recurrence rate of syncope with an arrhythmic cause. In 
addition, conduction disturbance in terms of bifascicular block was a strong predictor of an 
underlying bradyarrhythmia (i.e. intermittent complete heart block) as the cause of a 
clinically adjudicated arrhythmia-caused syncope. 
Finally, in study IV patients with incident AF during postoperative inpatient care after CABG 
surgery often suffered recurrent AF during the first 30 postoperative days. Patients with AF 
had higher CHA2DS2-VASc scores than patients who remained in sinus rhythm, and the ILR 
was more effective than the handheld ECG in identifying patients with AF. Furthermore, the 
AF burden was low.  
7.2 THE MYSTERY OF DEVICE-DETECTED AF REMAINS UNRESOLVED 
Previous studies (52-56) have shown that device-detected AF is common in the pacemaker 
population, and the total incidence of 30% in our study is in line with results from these 
aforementioned studies. It ranged from 30-55%, depending on whether patients with a history 
of clinical AF were included (53, 54) or not (55, 56). The high incidence of device-detected 
AF in our study and other studies can be explained by the fact that it reflects the pacemaker 
population in general. Conduction disturbances requiring the implantation of a pacemaker are 
usually associated with older populations, and age is acknowledged to be one of the strongest 
risk factors for incident AF (167, 168). Belonging to an older age group also means that the 
person has had more time to accumulate other comorbidities, some of which may be true risk 
factors for AF. Given this reasoning, as expected, we found an association between a high 
CHA2DS2-VASc score and clinical/known AF, as several components of the CHA2DS2-







overwhelming majority of the episodes with device-detected AF were asymptomatic, at least 
not so symptomatic that the patients visited the emergency department. Of course, we cannot 
rule out that symptoms were under-reported, as our study was observational, though similar 
numbers have been demonstrated in earlier studies (51, 169). Again, comorbidity may be a 
contributing factor to these findings, as competing symptoms can conceal or resemble 
symptoms which are actually due to episodes of AF. 
In contrast to previous studies (53, 56, 59, 63), we could not establish an association between 
device-detected AF and increased risk of ischaemic stroke. Furthermore, the annual 
ischaemic stroke incidence was low in our study population compared to earlier reports from 
device patients (170), and even compared to the general population (171). Several factors 
may have contributed to these findings. These include, first, the sample size. Second, the high 
proportion of patients with device-detected AF who received OAC treatment in our study. Of 
note, it may be worth pointing out here that most of the patients in our study began OAC 
treatment before 2016, and first in the ESC 2016 AF guidelines were clinical AF and device-
detected AF distinguished as two different entities (172). Third, these patients had regular 
healthcare appointments associated with pacemaker treatment, which may favour assessment 
and treatment for stroke-risk factors. Finally, their heart rhythm was continuously monitored 
through the pacemaker, and there was a particular awareness of observed arrhythmias in our 
study.  
There remains a knowledge gap whether device-detected AF should be treated with OAC 
treatment, and if so, whether there is a specific cut-off value for the AF burden when benefit 
exceeds risk. Even though guidelines generally agree that a high AF burden motivates 
assessment for OAC treatment (20, 41), there are no randomised trials on the topic, though 
there are several observational studies and some systematic reviews. A report from the 
ASSERT trial demonstrated increased risk of stroke and systemic embolism only for patients 
with device-detected AF lasting over 24 hours (75). However, in the next few years results 
are expected from three ongoing randomised trials: ARTESiA (NCT01938248), NOAH-
AFNET 6 (NCT02618577) and SILENT (NCT02004509), and these should provide some 









7.3 THE EFFECTIVENESS OF AN ILR IN SYNCOPE PATIENTS IS AFFECTED 
BY GENDER, BUT NOT BY AGE OR PRE-IMPLANT EVALUATION 
Syncope is common but remains challenging due to its often infrequent and unpredictable 
nature. As such, an ILR is an appealing tool for enabling long-term ECG monitoring. 
Syncope patients often undergo an extensive diagnostic workup which provides no indication 
of the underlying syncope mechanism (117). This is not particularly unexpected, as 
monitoring at the precise onset of syncope is the key to finding the syncope mechanism. Our 
findings with the same diagnostic yield, irrespective of the extent of the workup, are in line 
with a previous study (118) and are quite encouraging. There may be potential for saving 
time and healthcare resources by considering an ILR early in the evaluation of patients from 
older age groups with recurrent unexplained syncope, where a detailed history has not 
revealed the syncope mechanism. Earlier studies have indicated that an ILR can be more 
cost-effective than conventional testing in syncope patients (120, 121). This reasoning is also 
in accordance with current guidelines, which advocate an ILR early in the evaluation of 
individuals with unexplained syncope who are not high-risk (100).  
Interestingly, we found no differences in the diagnostic yield in terms of age, due to the fact 
that non-arrhythmic syncope was common in younger patients. It may be at least as important 
to be able to exclude an arrhythmic cause and explain the syncope mechanism as it is to 
diagnose an arrhythmia.  
Somewhat more expected were our finding that older patients had a higher incidence of 
arrhythmic syncope than the younger age-groups, most often due to bradyarrhythmia. A 
theoretically appealing explanation for this finding is that fibrosis and sclerosis of the atrial 
myocardium and conduction system is the most common reason for acquired conduction 
disorders (173, 174), and these changes increase with age. It is well-known that the 
prevalence of arrhythmias increases with age (102), and this awareness is probably, in turn, 
the reason why patients over 60 years of age in our study underwent significantly fewer 
diagnostic tests upfront ILR implantation. It may reflect a higher clinical suspicion of 
underlying arrhythmic mechanism in this age category.  
Last, women in our study suffered a recurrence of syncope and received an ECG-based 
diagnosis more often than men. We can find no obvious explanation for this finding, but it 
may involve the evaluation of risk in individual patients and possible gender differences in 
the presentation of syncope (175, 176). Earlier studies have also observed gender differences 







7.4 BASELINE 12-LEAD ECG HELPS IN FINDING PATIENTS AT HIGH RISK 
OF CLINICALLY ADJUDICATED ARRHYTHMIA-CAUSED SYNCOPE 
Twelve-lead ECG is a simple and easily accessible investigation that can give clues to 
underlying structural or electrical heart disease. However, few studies have investigated the 
relationship between baseline 12-lead ECG and syncope mechanisms. We found that 
bifascicular block was strongly associated with a clinically adjudicated arrhythmia-caused 
syncope, most often due to bradyarrhythmia in terms of intermittent complete heart block. 
Bifascicular block occurred almost exclusively in patients over 60 years of age. This is a 
reasonable finding if bifascicular block is seen as an expression of delayed conduction of 
electrical signals in the heart as an underlying conduction disorder.  
Two previous observational cohort studies, have pointed in the same direction (115, 124), and 
a prospective cohort study did not find any additional value in treatment guided by an 
electrophysiology study compared to a strategy of direct permanent pacing (127). 
Furthermore, primary results from the randomised SPRITELY trial (NCT01423994) showed 
that a strategy of empiric permanent pacing in patients with syncope and bifascicular block 
resulted in a reduction in major adverse events, but not the proportion of patients with 
recurrence of syncope (126). Their conclusion was that permanent pacing is a preferred 
strategy in elderly patients with bifascicular block and few, but recent, syncope spells (126). 
Our findings agree with their conclusion, and we find it reasonable, in consultation with the 
patient, to consider permanent pacing instead of an implantable loop recorder in older 
patients with bifascicular block and unexplained syncope.  
7.5 AF AS A MARKER OF HIGH CARDIOVASCULAR RISK 
Previous reports have demonstrated that AF is common in the early postoperative period after 
CABG surgery (179, 180), and this is in line with our findings. However, we also observed 
that continued episodes of AF were especially common during the first month after surgery. 
This finding could possibly be explained by the fact that it takes some time for the 
inflammatory response associated with surgery (181, 182) to subside. Furthermore, some 
patients were diagnosed with AF several months after surgery. Most probably our study 
population represents a group of patients with relatively high cardiovascular comorbidity 
explains this finding, and many of the risk factors for cardiovascular disease are also risk 
factors for AF (20, 26). So far, few data have come to light on the course of postoperative 
AF. Our study had a small sample size, but our findings indicate that this is a high-risk group 
for developing AF, and that it may be cost-effective to invest screening resources for this 
group, improving detection of AF aiming at stroke reduction. The AF burden was low, but 







burden (183), and risk of ischaemic stroke increases with increased AF burden (184). 
However, it is not clear whether prolonged ECG monitoring with subsequent OAC initiation 
for AF has an effect on stroke recurrence. More will be known about this when results from 
the LOOP study (NCT02036450), which aims to evaluate whether screening for AF with an 
ILR, and initiating OAC if AF is detected, will reduce the risk of ischaemic stroke or 
systemic embolism in patients with stroke risk factors, will be published (185).  
The question whether the very existence of AF is the root of the problem, or whether it 
involves the presence of multiple cardiovascular risk factors, so that AF rather is a risk-
marker remains to be answered. This argument has also been raised in the debate about 
device-detected AF, i.e. that subclinical AF/AHREs are a marker for patients at high risk of 
ischaemic stroke rather than the actual cause. Intracardiac thrombus formation and 
cardioembolic stroke need not to be caused by AF itself, but instead a consequence of atrial 
cardiomyopathy. To develop this idea further, the association between clinical AF and 
vascular dementia observed in study I, and demonstrated in earlier studies (186), is probably 
not only due to the presence of AF, i.e. on the casual pathway. Instead, it is the result of a 
number of factors, including high cardiovascular risk-factor load and underlying atrial 
cardiomyopathy. 
AF and subclinical AF/AHREs should be treated with OAC according to the guidelines (20), 
but OAC treatment neither reduces AF episodes nor relieves AF symptoms. Instead, it 
reduces possible future negative effects like ischaemic stroke and dementia (24, 35).  
7.6 LIMITATIONS 
Study I is an observational study, and accordingly poses a risk of bias due to unmeasured 
confounders. Nevertheless, observational studies play an important scientific role in 
generating hypotheses, and data can be adjusted for known confounders. The strength of this 
study is that all consecutive patients within a county were included, and it can therefore report 
real-world data about the pacemaker population. As the entire cohort consisted of patients 
with an indication for pacemaker implantation, we had no control group of patients with 
device-detected AF but no indication for pacing. Therefore, as patients with sinus node 
disease and AV block are often of advanced age and have comorbidities, the ischaemic stroke 
risk associated with device-detected AF may have been overestimated, i.e. not solely 
dependent on the occurrence of device-detected AF. Instead, it may have represented an 
overall high ischaemic stroke risk due to advanced age and multiple risk factors. The same 
reasoning applies to the group with clinical/known AF at implantation, and it can be argued 







ischaemic stroke and dementia in general. There is emerging evidence that AF is often 
associated with overt or hidden cardiovascular disease (187, 188). 
Studies II and III were observational studies, and hence also carry the risk of unmeasured 
confounding. The cohort was recruited from syncope patients who, after initial investigation, 
were either referred to a cardiologist or hospitalised due to syncope, which means that there 
was a selected group of syncope patients, i.e. selection bias. Our cohort is likely to represent 
patients with a slightly higher risk of underlying arrhythmia, rather than the syncope 
population as a whole. All patients had a clinical indication for an ILR, and we had no control 
group of patients with no ILR. As selecting patients is an aspect of internal validity, and 
internal validity is a pre-requisite for external validity, the results from these studies should be 
interpreted in their proper context and not generalised to the syncope population as a whole. 
On the other hand, the strength of the studies is that they represent real experience of the use 
and diagnostic yield of an ILR in syncope patients.  
Study IV was a prospective cohort study and should theoretically be less exposed to biases 
and confounding. The cohort constituted a subgroup of patients in the AFAF study, and as the 
patients were not recruited by randomisation but through questioning, there is a risk of 
selection bias. The gender distribution was somewhat skewed, with only one of 40 patients 
being a woman. Furthermore, the small sample size brings a degree of uncertainty to the 
results and its generalisability to the general population. Moreover, we cannot exclude the 
possibility that some patients had asymptomatic AF before inclusion, as they were not 
monitored prior to surgery. The interpretation of the ECG recordings was not blinded, and 
accordingly there is a risk of information bias in terms of differential misclassification, i.e. we 
may have been more prone to classify a recording as AF if it was in line with our hypothesis. 
To address this risk, recordings interpreted as AF by primary investigator always underwent a 
second interpretation by a second investigator. Additional strength of the study is the low 
number of dropouts. Regarding the nature of confounders, we know that postoperative AF is 
associated both with CABG surgery and the risk of having a future diagnosis of AF (146, 












CIEDs are a valuable resource in arrhythmia diagnostics, and can provide guidance in making 
clinical decisions. 
Asymptomatic episodes of subclinical AF/AHREs were common in the pacemaker 
population, and were associated with older age and congestive heart failure. The ischaemic 
stroke incidence was low, most likely due to the high proportion of patients receiving OAC 
treatment. Nevertheless, clinical/known AF was associated with increased risk of developing 
vascular dementia.  
In syncope patients receiving an ILR bifascicular block at baseline 12-lead ECG was a strong 
predictor of a clinically adjudicated arrhythmia-caused syncope, with the most common cause 
being an underlying bradyarrhythmia due to intermittent complete heart block. It would 
therefore seem reasonable to consider direct permanent pacing without further investigation 
in older patients with bifascicular block and unexplained syncope.   
Recurrence of syncope was more common in women than in men, a difference mainly driven 
by a higher incidence of syncope with non-arrhythmic cause. Patients ≥60 years of age had 
the lowest rate of pre-implant tests, probably because of a strong clinical suspicion of an 
underlying arrhythmia, and they also had the highest rate of arrhythmic syncope. 
In patients treated with CABG surgery, those with incident AF during hospitalisation had a 
high recurrence rate, most often within the first 30 postoperative days. AF recurrence after the 
first month was less frequent. The CHA2DS2-VASc score was higher in patients with AF than 
patients who remained in sinus rhythm. Handheld ECG identified fewer than half of the 














9 CLINICAL IMPLICATIONS 
Where AHREs are detected, the diagnosis should be verified by e.g. intracardiac EGMs, and 
the patient should be assessed in terms of indication for OAC treatment. Moreover, stroke-
risk factors should be addressed (20). Therefore, there is potential value in diagnosing 
subclinical AF/AHREs early, as it enables physicians to assess the patients for OAC 
treatment according to current guidelines, potentially offer them treatment, and initiate 
appropriate lifestyle interventions. However, results are awaited from randomised trials on 
the benefit of OAC treatment in this population.  
In evaluating syncope patients, gender has implications for the rate of syncope recurrence 
while the number of diagnostic tests upfront ILR implantation does not impact the diagnostic 
yield. In individual patients, given a non-diagnostic workup, in combination with a risk 
assessment with raised concerns of an underlying arrhythmia, it may be reasonable to bypass 
aspects of recommended investigations (100) in favour of long-term ECG monitoring. As 
bifascicular block proved to be a strong predictor of a clinically adjudicated arrhythmia-
caused syncope due to bradyarrhythmia with intermittent complete heart block, we propose 
adopting a more liberal attitude in terms of considering direct permanent pacemaker in these 
patients.  
After CABG surgery, episodes of incident AF are common during the early postoperative 
period, but a proportion of AF diagnoses were detected later, during the out-of-hospital 
monitoring period. Detecting these episodes is of clinical interest, due to the fact that AF in 
this setting is associated with increased mortality and morbidity (137, 145, 146, 149, 189, 
190), and that both European (20) and American (26, 77) AF guidelines recommend 
considering long-term OAC treatment in patients with postoperative AF with stroke-risk 
factors. In brief, our study indicated that long-term ECG monitoring, especially during the 
first 30 postoperative days, had a high yield of incident and recurrent AF episodes. Thus, 
after the first month, the AF incidence and recurrence rate was low. Our study is small and 
should be seen as hypothesis-generating, but long-term ECG monitoring seems most 











10 FUTURE PERSPECTIVES 
It is well-established that clinical AF increases the risk of ischaemic stroke, and that these 
patients benefit from OAC treatment in the presence of stroke-risk factors. However, the 
knowledge is more limited when it comes to device-detected AF, i.e. subclinical AF and 
AHREs. If the three ongoing randomised trials (ARTESiA (NCT01938248), NOAH-AFNET 
6 (NCT02618577) and SILENT (NCT02004509)) evaluating the benefit of OAC treatment 
for ischaemic stroke incidence in patients with subclinical AF/AHREs (78-80) are positive 
we can expect that device monitoring will become more important. On the contrary, if they 
are negative observational studies will become more important for studying the effect of AF 
burden.  
A closely related matter involves whether there is a cut-off value for subclinical AF/AHRE 
burden when OAC treatment results in a positive net benefit, or whether there is a continuing 
increased risk following increased subclinical AF/AHRE burden? The obvious reason why 
this is difficult to clarify is that it is not possible to study it within the framework of 
randomised trials, though it would be possible through observational studies. A large 
observational study conducted in a country with high-quality registers (e.g. Sweden) could be 
a complement to aforementioned large randomised trials. Furthermore, a number of factors 
need to be taken into consideration, such as whether the total subclinical AF/AHRE burden is 
the important issue, or whether the number of episodes or the longest duration of a single 
episode of subclinical AF/AHRE are of importance? 
Despite the fact that subclinical AF/AHREs are associated with increased risk of ischaemic 
stroke, no temporal relationship has been shown between the occurrence of subclinical 
AF/AHREs and ischaemic stroke. This raises a question about the true mechanism involved 
in ischaemic stroke in patients with subclinical AF/AHREs. More recently, the state of atrial 
cardiomyopathy has attracted more attention. Atrial cardiomyopathy contributes to a 
prothrombotic milieu, and perhaps the occurrence of subclinical AF/AHREs is an expression 
of a diseased atria, and an indication of patients at high risk for ischaemic stroke rather than 
the actual cause. Moreover, patients with AF often have associated cardiovascular diseases. It 
would therefore be interesting to investigate the most important action in AF clinics for 
reducing the symptom burden in AF patients. In future, treatment may be more focused, and 
there may be specialist clinics for risk-factor prevention.  
Does postoperative AF pose the same risk of ischaemic stroke as other types of AF? In study 
IV, we found that episodes of AF were common in patients both with and without incident 
AF during inpatient care. Is the presence of AF the key factor, or does it simply indicate a 







inflammatory activation, who might benefit from OAC treatment independent of AF? It 
would have been interesting to see the outcome of a clinical trial randomising patients with 
postoperative AF after CABG surgery to either OAC or antiplatelet drugs, or to see the 
results of a clinical trial randomising to extended diagnostics and treatment.    
What is the way forward in terms of improving estimates of risk of ischaemic stroke in 
patients with clinical AF or device-detected AF? Do their different characteristics matter, and 
what is the significance of frequent or short runs of supraventricular extrasystoles not 
fulfilling the criteria for AF diagnosis? Or should biomarkers, which can reveal myocardial 
stretch, disturbed hemostasis and general inflammatory activation in the cardiovascular 
system, be considered sufficient for estimating the risk of ischaemic stroke?   
Another interesting topic making considerable progress is artificial intelligence (AI). AI has 
shown promising results in diagnosing AF from ECGs in sinus rhythm (191). The AI network 
can identify subtle ECG patterns not visible to the human eye, and has great potential for 
improving the effectiveness of ECG screening. Perhaps AI in future can help analysing the 
atrial signal in patients with CIEDs to identify those at high risk of ischaemic stroke? Our 
results from studies II and III showed that it is difficult to predict syncope mechanism from 
pre-implant characteristics other than bifascicular block. In the light of this, it would be 
interesting to see if AI can also help to discern which syncope patients are at high risk of 
arrhythmic syncope in future. Because AI analyses require a large amount of data, it may be 
















11 SVENSK SAMMANFATTNING 
11.1 BAKGRUND 
Gemensamt för samtliga kardiovaskulära implanterbara device som pacemakers och 
diagnostiska hjärtmonitorer är att de möjliggör kontinuerlig registrering av hjärtats rytm. 
Eftersom tiden som hjärtat övervakas har stor betydelse för hur mycket rytmrubbningar man 
hittar utgör implanterbara device en stor diagnostisk möjlighet.  
Patienter som är i behov av implanterbara device är vanligtvis äldre, vilket innebär att de ofta 
har riskfaktorer för den vanligaste hjärtrytmrubbningen med klinisk relevans nämligen 
förmaksflimmer. Förutom ålder är hypertoni, diabetes, övervikt, alkohol och underliggande 
hjärtsjukdom exempel på riskfaktorer för förmaksflimmer, men förmaksflimmer kan också 
debutera efter en större operation sannolikt pga. en kombination av vätskebrist, stresspåslag 
och inflammation i operationsområdet. Förmaksflimmer innebär att hjärtat slår oregelbundet, 
men inte alla patienter har symptom. Det är dock viktigt att upptäcka förmaksflimmer 
eftersom det obehandlat innebär en kraftigt ökad risk för stroke hos de flesta individer. 
Behandling med blodförtunnande läkemedel som är indicerat hos de flesta med 
förmaksflimmer minskar risken för stroke med nästan 70%.  
En pacemaker består vanligtvis, förutom av själva dosan där batteriet finns, av två elektroder, 
en som är placerad i hjärtats högra kammare och en som är placerad i hjärtats högra förmak. 
Via dessa elektroder övervakas hjärtats rytm kontinuerligt och episoder med snabb frekvens i 
förmaket kan detekteras och sparas. Dessa episoder kallas device-detekterat förmaksflimmer 
och innebär ökad risk för stroke även om riskökningen inte tycks vara lika stor som vid 
förmaksflimmer dokumenterat med 12-avlednings elektrokardiogram (EKG) och nyttan av 
blodförtunnande behandling hos dessa patienter är ännu inte bevisad. 
Svimning innebär en kort medvetandeförlust. Det finns många möjliga orsaker till svimning, 
varav en kan vara en rubbning i hjärtrytmen. Det är ofta svårt att fånga själva rytmrubbningen 
på akutmottagningen eftersom EKG registreringen måste göras just vid tillfället för 
svimningen. Med hjälp av en implanterbar hjärtmonitor som opereras in precis under huden 
på vänstra sidan av bröstkorgen kan hjärtats rytm övervakas under en längre tid med 
möjlighet till EKG registrering vid förnyad svimning, vilket kan avslöja om den 
underliggande mekanismen till svimningen är en hjärtrytmrubbning. 
Syftet med denna avhandling är att belysa olika aspekter av hjärtrytmrubbningar 
diagnostiserade med implanterbara device. I studie I beskrivs förekomsten av device-







behandling och förekomst av ischemisk stroke och vaskulär demens. Studie II och III berör 
patienter som erhållit en implanterbar hjärtmonitor pga. svimning. I studie II tittade vi på om 
fynd på 12-avlednings EKG kunde prediktera mekanismen till svimningen och i studie III 
undersökte vi om ålder och kön påverkade dels utredningen innan implantationen av 
hjärtmonitorn samt det diagnostiska utbytet av hjärtmonitorn. I det fjärde delarbetet 
undersökte vi med hjälp av en implanterbar hjärtmonitor om patienter som fått 
förmaksflimmer precis efter att de genomgått en operation av hjärtats kranskärl hade stor risk 
att återfå förmaksflimret under 12-månaders tid. Därtill ville vi beräkna total tid patienterna i 
genomsnitt tillbringar i förmaksflimmer s.k. förmaksflimmerbörda.  
11.2 METOD OCH RESULTAT 
I studie I inkluderades konsekutiva patienter i Region Halland under åren 2010–2014 som 
erhållit en pacemaker med förmakselektrod. Under uppföljningen noterades förekomst av 
device-detekterat förmaksflimmer och insättande av blodförtunnande behandling hos 
patienter utan känt förmaksflimmer. Hos patienter med känt förmaksflimmer vid 
implantationen noterades förändring av blodförtunnande behandling. Uppföljningstiden för 
detektion av device-detekterat förmaksflimmer var till slutet av 2015 och vid slutet av 2017 
inhämtades data avseende förekomst av ischemisk stroke och vaskulär demens via Regionalt 
Patientregister. Vid inklusion hade 271 patienter känt förmaksflimmer och av dem hade 80% 
(216/271) pågående blodförtunnade behandling. Fyrahundra elva patienter hade inte någon 
känd förmaksflimmerdiagnos och av dem diagnostiserades 30% (125/411) med device-
detekterat förmaksflimmer under uppföljningstiden på 38 månader (medel). Av dessa 
förskrevs 62% behandling med blodförtunnade läkemedel. Hjärtsvikt (p= .03) och ålder >75 
år (p= .0002) var riskmarkörer för att utveckla device-detekterat förmaksflimmer. Den årliga 
stroke risken var 2.1% hos patienter med känt förmaksflimmer jämfört med 1.9% hos 
patienter med device-detekterat förmaksflimmer och 1.4% hos patienter helt utan någon typ 
av förmaksflimmer. Vaskulär demens förekom hos 11.2% av patienterna med känt 
förmaksflimmer jämfört med 6.2% av patienterna utan förmaksflimmer (p= .048) samt 5.6% 
av patienterna med device-detekterat förmaksflimmer (p= .09). 
Studiepopulationen i studie II och III bestod av konsekutiva patienter i Region Halland som 
under åren 2007–2016 erhållit en implanterbar hjärtmonitor på indikationen svimning. Notera 
skillnaden mellan de två begreppen diagnos via hjärtmonitorn (studie II) och EKG-baserad 
diagnos (studie III). Diagnos via hjärtmonitorn innefattar alla patienter där hjärtmonitorn gett 
vägledning i diagnostiken dvs. där det funnits EKG registreringar både vid förnyad svimning 
eller andra tillfällen som möjliggjort att man kunnat ställa en klinisk diagnos. EKG-baserad 







Totalt inkluderades 300 patienter, varav 49% (n=147) var kvinnor. Medelålder 66±16 år. I 
studie II erhöll 49% (146/300) av patienterna en diagnos via hjärtmonitorn. Patienter med 
bifascikulärt block på 12-avlednings EKG erhöll oftare en diagnos via hjärtmonitorn 76% 
(25/33) jämfört med de med normalt 12-avlednings EKG 44% (90/205), p< .001. Bland de 
med bifascikulärt block på 12-avlednings EKG erhöll 96% (24/25) en klinisk diagnos av 
bakomliggande hjärtrytmrubbning som orsak till sin svimning, av vilka 23 hade en EKG 
registrering med bradykardi (långsam hjärtrytm). Bifascikulärt block förekom nästan 
uteslutande hos de ≥60 år (31/33). Justerat odds ratio för att erhålla en klinisk diagnos av 
svimning pga. hjärtrytmrubbning vid bifascikulärt block var 5.5 (95%CI 2.3–13.2), p< .001. 
Positivt prediktivt värde för bifascikulärt block att prediktera en klinisk diagnos av svimning 
pga. hjärtrytmrubbning var 73%, och negativt prediktivt värde var 73%. Inga andra fynd på 
12-avlednings EKG påverkade utfallet av långtids-EKG registreringen. I studie III sågs att 
kvinnor oftare än män hade förnyad svimning och erhöll en EKG-baserad diagnos (kvinnor: 
56/147, 38%; män: 33/153, 22%; p= .001), framförallt utgjordes skillnaden mellan kvinnor 
och män av svimning pga. annan orsak än hjärtrytmrubbning dvs normal EKG registrering 
vid tillfället för ny svimning (kvinnor: 27/147, 18%; män: 15/153, 10%; p= .045). Patienter 
≥60 år genomgick färre diagnostiska test innan implantationen av hjärtmonitorn, men hade 
högre förekomst av förnyad svimning pga. hjärtrytmrubbning (<40 år: 3/11, 27%; 41–59 år: 
7/18, 39%; and ≥60 år: 37/60, 62%; p= .045). Bradykardi var vanligast bland de ≥60 år (<40 
år: 1/11, 9%; 41–59 år: 5/18, 28%; and ≥60 år: 33/60, 55%; p= .06). Dessutom hittades hos 
en fjärdedel av patienterna utan förnyad svimning EKG registreringar som kan indikera 
svimning pga. hjärtrytmrubbning. 
Studie IV var en substudie till den prospektiva studien som på engelska förkortas AFAF 
study. I korthet utvärderar studien förekomsten av förmaksflimmer hos 250 patienter som 
genomgått perkutan koronar intervention eller operation av hjärtats kranskärl genom att 
jämföra icke-invasiv handhållen EKG-registrering tre gånger om dagen under första månaden 
och därefter två veckor vid tre, 12 och 24 månader efter operation med rutinsjukvård. I 
substudien genomgår patienterna som tillägg kontinuerlig monitorering med en implanterbar 
hjärtmonitor. Primärt utfallsmått var andelen av patienter som återföll eller diagnostiserades 
med nytt förmaksflimmer under 12-månaders uppföljning, medan sekundära utfallsmått var 
förmaksflimmerbörda och andelen som utvecklade persisterande (ihållande) förmaksflimmer. 
Tjugosju (68%) av patienterna diagnostiserades med förmaksflimmer, 21 under 
sjukhusvistelsen och sex patienter under uppföljningstiden. Arton (67%) av dem hade mer än 
en episod av förmaksflimmer, varav en patient utvecklade persisterande förmaksflimmer. Två 
patienter utvecklade persisterande förmaksflimmer redan vid deras första 







postoperativa dagarna, då 17/40 patienterna hade minst en episod med förmaksflimmer under 
denna tid. Efter de första 30 dagarna, nydiagnostiserades bara tre patienter med 
förmaksflimmer och 10 patienter återföll i förmaksflimmer. Hos patienter med paroxysmalt 
förmaksflimmer var förmaksflimmerbördan låg, 0.1% (interkvartilavstånd 0.28). Patienter 
med förmaksflimmer hade högre poäng på CHA2DS2-VASc skalan (beslutsstöd 
inkluderandes riskfaktorer för stroke för att värdera indikation av blodförtunnande läkemedel 
vid förmaksflimmer) jämfört med patienterna som behöll sinusrytm (median 4, 
interkvartilavstånd 1; median 3, interkvartilavstånd 2; p= .006). Handhållen EKG-registrering 
tre gånger dagligen identifierade 45% (9/20) av patienterna med förmaksflimmer 
identifierade via hjärtmonitorn, p= .001.  
11.3 SLUTSATSER 
Kardiovaskulära implanterbara device utgör genom sin kontinuerliga övervakning en stor 
möjlighet för diagnostik av hjärtrytmrubbningar samt för vägledning vid kliniska beslut. 
Asymptomatiska episoder av device-detekterat förmaksflimmer var vanligt hos 
pacemakerpatienter och associerat med högre ålder samt hjärtsvikt. Förekomsten av 
ischemisk stroke var låg troligtvis pga. att en stor andel av patienterna behandlades med 
blodförtunnande läkemedel. Däremot var känt förmaksflimmer associerat till ökad risk för 
vaskulär demens.  
Hos patienter med synkope som erhöll en implanterbar hjärtmonitor predikterade 
bifascikulärt block på 12-avlednings EKG en framtida klinisk diagnos av bakomliggande 
hjärtrytmrubbning som orsak till svimning, oftast pga. bradykardi orsakat av totalblock. 
Därav är det rimligt att överväga direkt pacemakerimplantation istället för att implantera en 
hjärtmonitor hos äldre patienter med bifascikulärt block och oförklarad svimning.  
Kvinnor svimmade pånytt oftare än män, en skillnad som huvudsakligen drevs av att kvinnor 
oftare återföll i svimning pga. annan orsak än hjärtrytmrubbning. Patienter ≥60 år genomgick 
färre diagnostiska test innan implantation av en hjärtmonitor, troligtvis pga. hög misstanke 
om svimning orsakat av en hjärtrytmrubbning. Patienter ≥60 år hade också den högsta 
förekomsten av svimning pga. hjärtrytmrubbning.  
Patienter med förmaksflimmer under den postoperativa sjukhusvistelsen efter 
kranskärlsoperation hade hög förekomst av återfall av förmaksflimmer, speciellt under de 
första 30 postoperativa dagarna. Därefter var återfallsfrekvensen låg. Handhållen EKG-
registrering identifierade mindre än hälften av patienterna med förmaksflimmer på 
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